

1 Timothy Devlin (admitted pro hac vice)  
James Gorman III (to be admitted pro hac vice)  
2 Devlin Law Firm LLC  
3 1306 N. Broom Street, 1<sup>st</sup> Floor  
Wilmington, DE 19806  
4 Telephone: (302) 449-9010  
5 Facsimile: (302) 353-4251  
6 Email: tdevlin@devlinlawfirm.com  
jgorman@devlinlawfirm.com  
7

8 Greg Gardella (to be admitted pro hac vice)  
Gardella Grace P.A.  
9 455 Massachusetts Ave, NW, Suite 507  
10 Washington, DC 20001  
Telephone: 703-556-9600  
11 Facsimile: 703-740-4541  
12 Email: ggardella@gardellagrace.com

13 Ellisen S. Turner  
14 Irell & Manella LLP  
15 1800 Avenue of the Stars, Suite 900  
Los Angeles, CA 90067  
16 Telephone: 310-203-7901  
17 Facsimile: 310-203-7199  
18 Email: eturner@irell.com

19 Seth W. Wiener (California State Bar No. 203747)  
Law Offices of Seth W. Wiener  
20 9107 Wilshire Boulevard, Suite 450  
21 Beverly Hills, CA 90210  
22 Telephone: (925) 487-5607  
23 Email: sethwiener@yahoo.com

24 Attorneys for Plaintiff  
25 FULFILLIUM, INC.  
26  
27  
28

**UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA**

FULFILLIUM, INC.,

Plaintiff,

vs.

RESHAPE MEDICAL LLC, SV  
HEALTH INVESTORS, LLC, AND  
RESHAPE LIFESCIENCES, INC.

Defendants.

Case No. 2:17-cv-08419-RGK-PLA

**SECOND AMENDED COMPLAINT  
FOR TRADE SECRET  
MISAPPROPRIATION AND  
PATENT INFRINGEMENT**

**DEMAND FOR JURY TRIAL**

RESHAPE MEDICAL LLC,

Counter-Plaintiff,

v.

FULFILLIUM, INC.,

Counter-Defendants.

1 Plaintiff Fulfillium, Inc. (“Fulfillium” or “Plaintiff”), for its  
2 Complaint against ReShape Medical LLC (“ReShape Medical LLC”), SV  
3 Health Investors, LLC (“SV Health”), and ReShape Lifesciences Inc.  
4 (“ReShape Lifesciences”)(collectively “Defendants”) alleges the following:

5 **NATURE OF THE ACTION**

6 1. This is an action for trade secret misappropriation and patent  
7 infringement arising under the Uniform Trade Secrets Act, CA. Civ. Code §3426  
8 *et seq.* and/or Mass. Gen. Laws ch. 93, § 42-42A and the Patent Laws of the  
9 United States, 35 U.S.C. § 1 *et seq.*

10 **THE PARTIES**

11 2. Fulfillium is a corporation organized and existing under the laws of  
12 the State of Delaware, with an address at 1136 Orchard Avenue, Napa, California  
13 94558.

14 3. On information and belief, ReShape Medical LLC is a limited  
15 liability company organized and existing under the laws of the State of Delaware  
16 with its principal place of business at 100 Calle Iglesia, San Clemente, California  
17 92672. ReShape Medical LLC can be served via its registered agent The  
18 Corporation Trust Company, Corporation Trust Center, 1209 Orange Street,  
19 Wilmington, Delaware, 19801. ReShape Medical LLC is a wholly owned  
20 subsidiary of ReShape Lifesciences and the surviving entity of the merger of a  
21 subsidiary of ReShape Lifesciences and ReShape Medical, Inc.

22 4. On information and belief, SV Health is a limited liability company  
23 organized and existing under the laws of the State of Delaware with its principal  
24 place of business at One Boston Place, 201 Washington Street, Suite 3900,  
25 Boston, Massachusetts 02108. SV Health Investors can be served via its registered  
26 agent The Corporation Trust Company, Corporation Trust Center, 1209 Orange  
27 Street, Wilmington, Delaware, 19801. SV Health maintains a business in the  
28 State of California at 1700 Owens Street, Suite 585, San Francisco, CA 94158.

1           5.     On information and belief, ReShape Medical LLC’s predecessor,  
2 ReShape Medical, Inc., was founded, funded, owned and controlled in relevant  
3 respect by SV Life Sciences, LLC, which has reorganized as SV Health Investors,  
4 LLC. The website of SV Health Investors states that “SV Health Investors,  
5 formerly SV Life Sciences, is a leading healthcare and life sciences venture  
6 capital and growth equity firm.” SV Health Investors and its predecessor SV Life  
7 Sciences have at all relevant times held one or more seats on ReShape Medical,  
8 Inc.’s Board of Directors.

9           6.     The first heading of the About Us page of SV Health Investors’  
10 website is “Hands-on business partners.” Exhibit 5. The page explains that SV  
11 Health Investors “work hands-on with our portfolio companies as trusted advisers  
12 and partners from formation to exit. We help them develop business strategy,  
13 make connections within our networks, and guide them through both smooth and  
14 turbulent times toward a successful exit.” *Id.* According to the website, “[t]he SV  
15 team has more than 400 aggregate years of healthcare operating experience –  
16 which means we can work as true partners with our entrepreneurs, and develop  
17 strong relationships with them through the full life cycle of their ventures.” *Id.*

18           7.     On information and belief, SV Health and its predecessor SV Life  
19 Sciences have directed, controlled, actively induced and/or conspired with  
20 ReShape Medical, Inc., and subsequently ReShape Medical LLC, to take the  
21 actions that form the basis for this Second Amended Complaint.

22           8.     On information and belief, ReShape Lifesciences is a corporation  
23 organized and existing under the laws of the State of Delaware with its principal  
24 place of business at 1001 Calle Amanecer, San Clemente, California 92673.  
25 ReShape Lifesciences can be served via its registered agent The Corporation Trust  
26 Company, Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801.  
27 ReShape Lifesciences is the corporate parent of ReShape Medical LLC and  
28

1 ultimate bearer of certain liabilities of the now merged and extinguished entity,  
2 ReShape Medical, Inc.

3 9. On October 2, 2017, EnteroMedics, Inc. acquired ReShape Medical,  
4 Inc. for cash and securities in the value of approximately \$38 million. This  
5 acquisition and merger was announced on October 3, 2017.  
6 <http://ir.enteromedics.com/releasedetail.cfm?ReleaseID=1042545>. ReShape  
7 Medical LLC is an additional entity that resulted from this merger. On October  
8 23, 2017, EnteroMedics, Inc. announced its name change to ReShape Lifesciences  
9 Inc. <http://ir.enteromedics.com/releasedetail.cfm?ReleaseID=1044913>.

### 10 JURISDICTION AND VENUE

11 10. Upon information and belief, each of ReShape Medical LLC and  
12 ReShape Lifesciences sell and offer to sell products and services throughout the  
13 United States, including in this judicial district, and introduces products and  
14 services into the stream of commerce that incorporate infringing technology  
15 knowing that they would be sold in this judicial district and elsewhere in the  
16 United States.

17 11. This is an action for trade secret misappropriation and patent  
18 infringement arising under the Uniform Trade Secrets Act, CA. Civ. Code §3426  
19 *et seq.* and/or Mass. Gen. Laws ch. 93, § 42-42A, and the Patent Laws of the  
20 United States, Title 35 of the United States Code, respectively.

21 12. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331  
22 and 1338(a).

23 13. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(b),  
24 (c), (d). On information and belief, each Defendant conducts business in this  
25 district, the claims alleged in this Complaint arise in this District, and acts of  
26 infringement have taken place and are continuing to take place in this District.  
27 Venue is proper in this judicial district under 28 U.S.C. § 1400(b). On  
28 information and belief, ReShape Medical LLC and ReShape Lifesciences have

1 committed acts of infringement in this District and have a regular and established  
2 place of business within this District.

3 14. On information and belief, each Defendant is subject to this Court's  
4 general and specific personal jurisdiction because each Defendant has sufficient  
5 minimum contacts within the State of California and this District, pursuant to due  
6 process and/or the California Long Arm Statute, because each Defendant  
7 purposefully availed itself of the privileges of conducting business in the State of  
8 California and in this District, because each Defendant regularly conducts and  
9 solicits business within the State of California and within this District, and  
10 because Fulfillium's causes of action arise directly from each Defendant's  
11 business contacts and other activities in the State of California and this District.

12 **GENERAL ALLEGATIONS**

13 15. Dr. Richard D. Y. Chen was born in Taiwan in 1958 and emigrated to  
14 the United States in 1972. Dr. Chen obtained an undergraduate degree in  
15 biochemistry and molecular biology from Harvard University in 1979. Dr. Chen  
16 next attended medical school at Northwestern University and obtained an M.D. in  
17 1983. Dr. Chen performed his internship in general surgery and continued in his  
18 residency in neurosurgery at the Johns Hopkins Hospital in the 1980s.

19 16. Dr. Chen obtained a Master's Degree in Business Administration  
20 from Stanford University in 1990. Following matriculation, Dr. Chen began  
21 working in the investment banking department at Morgan Stanley & Company.  
22 Thereafter, Dr. Chen continued working in financial services making investments  
23 in and assisting start-up companies primarily in the technology sector.

24 17. In 1999, Dr. Chen started conceiving innovative ideas of his own by  
25 combining his experiences at the crossroads of medicine and technology. After  
26 the tragic events of September 11, 2001, prospects in the technology investment  
27 markets began to slow. Dr. Chen decided to focus on developing and  
28 commercializing these ideas into entrepreneurial ventures.

1           18. Dr. Chen conceived of a bariatric medical device and procedure  
2 whereby a novel balloon device is delivered endoscopically to reduce the interior  
3 volume of the stomach and impede the flow of ingested food and thereby  
4 effectively reduce the calories consumed. To mitigate potentially fatal  
5 consequences of premature rupture and migration, which were significant  
6 deficiencies in earlier devices within this class, safety was provided by two or  
7 more chambers filled with fluids.

8           19. Because obesity is a complex, multifactorial disease, Dr. Chen  
9 invested at least two years' time i) analyzing critically over a thousand scientific  
10 papers relating from the genetic basis of obesity to interventions in clinical  
11 therapy to the psychosocial impact of the disease, and ii) attending scientific  
12 research conferences on the basic underpinnings of the field and major medical  
13 conferences in the United States and overseas to learn about the state of the art in  
14 therapy and how the various medical specialties played their role in its treatment.  
15 Gaining insight from these activities, Dr. Chen further refined key elements of his  
16 idea and its implementation into everyday medical practice.

17           20. Dr. Chen then presented his idea, on a confidential basis, to leading  
18 researchers and clinicians in the field, including the former presidents of the  
19 American Gastroenterology Association, the American Society of Bariatric  
20 Surgeons and its overseas counterpart, the International Federation for the Surgery  
21 of Obesity. Practically everyone he contacted responded favorably with the  
22 willingness to commit to participate further in developing the medical device and  
23 procedure. Each of these disclosures was subject to a mutual understanding and  
24 obligation of confidentiality. Only individuals who were under written  
25 obligations of confidentiality were provided information regarding Fulfillium's  
26 trade secrets.

27           21. Dr. Chen contributed funds and his intellectual property to form  
28 Fulfillium, Inc. in 2004 and filed his first provisional patent application on May 3,

1 2004. Dr. Chen raised seed capital from friends and family to take the idea to the  
2 next stage of development. Dr. Chen attended trade shows in medical device  
3 manufacture. Dr. Chen engaged consultants including engineers to help develop  
4 the device and former regulators to explore the pathway for FDA approval.  
5 Prototypes were constructed and animal lab facilities were evaluated.

6 22. Dr. Chen next embarked on raising venture capital to prove the  
7 concept. Given his past experience in the venture business, Dr. Chen adopted a  
8 set of practices for disclosure to protect the intellectual properties he developed.  
9 Under this set of practices, Dr. Chen did not disclose any trade secret information  
10 to anyone unless he had confirmed an agreement that it would be kept  
11 confidential. On January 25, 2005, Dr. Chen spoke with Dr. Samuel Wu, M.D. of  
12 SV Life Sciences (predecessor of SV Health) to discuss Fulfillium's technology  
13 on a confidential basis. All parties confirmed that the conversations regarding Dr.  
14 Chen's ideas were subject to an oral agreement of confidentiality. On February  
15 10, 2005, Dr. Chen attended a meeting including the SV Life Sciences team in  
16 Boston led by partner David Milne via a videoconference call hosted at the SV  
17 Life Sciences offices at 950 Tower Lane, Ste. 1535, Foster City, California. Dr.  
18 Chen understood the meeting to be confidential and, consistent with that, Dr.  
19 Chen's presentation slides were all marked "STRICTLY CONFIDENTIAL." All  
20 parties confirmed that the conversations surrounding this meeting were subject to  
21 an oral agreement of confidentiality.

22 23. In addition, SV Life Sciences representatives had due diligence calls  
23 with various Fulfillium scientific advisors. These due diligence phone calls were  
24 for expert validation of Fulfillium's therapeutic concept and did not include  
25 presentations of Fulfillium's product development plans or trade secrets.

26 24. Dr. Wu informed Dr. Chen that the due diligence was "looking good"  
27 and that SV Life Sciences was contemplating a term sheet. Dr. Wu noted that  
28 although he, in California, had taken a point person role in the development of the



1 deal, SV Life Sciences' medical device group was headquartered in Boston and he  
2 was not part of the group. Thus, going forward SV Life Sciences would prefer to  
3 partner with a venture capital firm in California who could more effectively  
4 monitor Fulfillium's activities.

5 25. Among other venture capital firms, Dr. Chen separately gave a  
6 confidential presentation to Sprout Partners. Dr. Chen delivered the presentation  
7 to Sprout partners Jeani Delagardelle at Sprout's Menlo Park office and Andrew  
8 Firlik, M.D. via conference call on March 4, 2005. Sprout and Fulfillium  
9 understood that the conversations surrounding this presentation were confidential  
10 because the parties previously signed and executed a written non-disclosure  
11 agreement. Ms. Delagardelle later invited Dr. Chen to attend as Sprout's guest at  
12 the annual American Heart Association luncheon, a key event in the industry. Ms.  
13 Delagardelle took on a lead role by referring another venture capital firm as a  
14 potential co-investor. Dr. Chen eventually made an introduction between SV Life  
15 Sciences and Sprout.

16 26. During the foregoing meetings and communications with SV Life  
17 Sciences and Sprout, Dr. Chen provided confidential and detailed disclosures of  
18 Fulfillium's preferred clinical trial design and regulatory approval strategy. All of  
19 the relevant parties to the foregoing meetings and communications understood the  
20 conversations that occurred were subject to either oral or written agreements of  
21 confidentiality.

22 27. On information and belief, neither SV Life Sciences nor Sprout had  
23 any substantial previous knowledge or experience with balloon treatments for  
24 obesity.

25 28. On information and belief, all of SV Life Sciences' and Sprout's  
26 knowledge concerning Dr. Chen's novel balloon designs for obesity as of the  
27 Spring of 2005 was supplied by Dr. Chen.

1           29. In the Spring of 2005, Ms. Delagardelle indicated that the due  
2 diligence process would be delayed somewhat due to the fact that the healthcare  
3 group principals of Sprout were forming a new firm, New Leaf Venture Partners.  
4 Ms. Delagardelle asked Dr. Chen if this would pose a problem. Dr. Chen  
5 responded that time was of the essence but a short delay under the circumstances  
6 would be manageable.

7           30. Meanwhile, Dr. Chen continued to interface with SV Life Sciences.  
8 SV Life Sciences arranged for Dr. Chen to meet George Wallace (venture partner  
9 for SV Life Sciences) on May 16, 2005 at a restaurant in Chicago. During the  
10 meeting Mr. Wallace proposed terms and conditions under which he would work  
11 with Fulfillium. In addition to other compensation, Mr. Wallace demanded  
12 greater than 25% stake in Fulfillium after the first round of financing by venture  
13 capital firms. Given the ownership dilution that typically occurs during the first  
14 round of financing, Mr. Wallace was effectively demanding majority ownership of  
15 Fulfillium. Dr. Chen noted that Mr. Wallace's requested equity share was more  
16 than two to four times greater than that typically allotted to a CEO brought in to  
17 run a company at Fulfillium's stage of development. Mr. Wallace offered no  
18 justification other than to say that he needed to compensate his business partner, a  
19 practicing radiologist in Minnesota, and would not proceed without including his  
20 business partner. Dr. Chen never disclosed the trade secrets to Mr. Wallace.

21           31. Thereafter, no further discussion took place between Mr. Wallace and  
22 Dr. Chen. Instead, unbeknownst to Dr. Chen, decision makers in SV Life  
23 Sciences sought to launch a new company with Mr. Wallace as the CEO based on  
24 Fulfillium's technology and trade secrets, which were misappropriated despite the  
25 repeated oral agreements of confidentiality with SV Life Sciences. In the early  
26 summer of 2005, Ms. Delagardelle of New Leaf sent a brief email to Dr. Chen  
27 advising that New Leaf was considering a deal that SV Life Sciences was  
28 proposing. Dr. Chen presumed that SV Life Sciences was proposing bringing to

1 market an alternative solution that would be different from the technology  
2 developed and confidentially disclosed by Dr. Chen. Dr. Chen would later  
3 discover that SV Life Sciences' venture headed by Mr. Wallace was premised not  
4 on some alternative solution but rather Fulfillium's technology and trade secrets.

5 32. On information and belief, Mr. Wallace's new company, called  
6 Abdominis, Inc., was formed during the summer of 2005 and was funded by New  
7 Leaf and SV Life Sciences. Upon information and belief, both SV Life Sciences  
8 and New Leaf not only provided capital, but as typical early stage venture capital  
9 firms, provided direct guidance in the company's development and controlled the  
10 operations of the company through their board membership.

11 33. Abdominis was subsequently renamed ReShape Medical, Inc.  
12 Hereafter, "Reshape Medical, Inc." will refer to Abdominis, Inc. and its successor-  
13 in-interest Reshape Medical, Inc.

14 34. As is typical for a medical start-up company, ReShape Medical, Inc.  
15 operated in "stealth mode" during development. ReShape Medical, Inc. started  
16 pivotal clinical trials in 2012 and applied for FDA approval in 2014. The FDA  
17 granted Pre-Marketing Approval to the ReShape Duo™ device and treatment  
18 method on July 28, 2015.

19 35. When ReShape Medical, Inc. emerged from stealth mode and began  
20 commercial operations, Dr. Chen learned that ReShape Medical, Inc. had copied  
21 his trade secrets, including his entire clinical trial "playbook." ReShape Medical,  
22 Inc. copied, among other things, Dr. Chen's clinical trial design and his selection  
23 of the principal investigator.

24 36. On information and belief, the board of directors and officers of  
25 ReShape Medical, Inc. knew or had reason to know of the foregoing facts and  
26 events at the time ReShape Medical, Inc. first submitted the ReShape Duo™  
27 product for FDA approval in 2012.

1           37. On October 2, 2017, EnteroMedics, Inc. acquired ReShape Medical,  
2 Inc. for cash and securities in the value of approximately \$38 million. This  
3 acquisition and merger was announced on October 3, 2017.  
4 <http://ir.enteromedics.com/releasedetail.cfm?ReleaseID=1042545>. ReShape  
5 Medical LLC is an additional entity that resulted from this merger. On October  
6 23, 2017, EnteroMedics, Inc. announced its name change to ReShape Lifesciences  
7 Inc. <http://ir.enteromedics.com/releasedetail.cfm?ReleaseID=1044913>.

8           38. Upon information and belief, as a result of the aforementioned  
9 merger, ReShape Medical LLC and ReShape Lifesciences Inc. are the entities that  
10 now hold the liabilities of ReShape Medical, Inc. Fulfillium reserves the right to  
11 include additional entities if it later discovers that ReShape Medical, Inc.’s  
12 liabilities have been transferred elsewhere as a result of the aforementioned  
13 merger.

14                           **COUNT I – TRADE SECRET MISAPPROPRIATION**

15           39. Fulfillium repeats the allegations of paragraphs 1-38 above as though  
16 fully set forth herein.

17           40. This claim is asserted against ReShape Medical LLC and SV Health  
18 for misappropriation of Fulfillium’s trade secrets and for conspiring to  
19 misappropriate such trade secrets.

20           41. The specific trade secrets that ReShape Medical, Inc., SV Health,  
21 and/or their agents misappropriated, despite the repeated oral and/or written  
22 agreements of confidentiality, include at least three aspects of Dr. Chen’s clinical  
23 trial “playbook.” Three key protocols in the playbook optimized the experimental  
24 rigor of the trial, especially in combination, in contrast to the typical product  
25 development approach to optimize the conditions for favorable outcomes. The  
26 first is the counterintuitive control arm that “stacked the deck” against the  
27 experimental arm. To tease out efficacy due to the device alone, the device  
28 therapy had to show statistically better results over the most efficacious non-

1 interventional therapy available, namely diet and exercise counseling. The second  
2 is the trial primary and secondary endpoints that set high bars for not just efficacy  
3 but clinical efficacy. To gain acceptance in the bariatric scientific community, not  
4 only the results have to be statistically significant, but the difference between the  
5 two arms had to be wide enough to warrant an interventional device therapy. The  
6 third is the counterintuitive and gastric device-focused principal investigator  
7 selection premise. To provide even further confidence in the results to overcome  
8 the stigma of gastric balloons, the trial was to be conducted under the watchful  
9 eyes of investigators of consummate skill and reputation. All of the above were  
10 developed after Dr. Chen's extensive study of the shortcomings of previous  
11 gastric devices.

12 42. Upon information and belief, based on EnteroMedics's acquisition of  
13 ReShape Medical, Inc. and the publically available regulatory documents relating  
14 to said merger, ReShape Medical LLC assumed all, or at least a portion of, the  
15 liabilities of ReShape Medical, Inc., including the present trade secret  
16 misappropriation claims. To the extent that ReShape Medical LLC has taken on  
17 the liability of ReShape Medical, Inc., it is liable for ReShape Medical, Inc.'s  
18 misappropriation; and/or to the extent ReShape Medical LLC continues to rely on  
19 and/or profit from ReShape Medical, Inc.'s misappropriation, it is liable for that  
20 continuing activity. Fulfillium reserves the right to assert this count against  
21 additional entities if it later discovers that ReShape Medical, Inc.'s liabilities have  
22 been transferred elsewhere as a result of the aforementioned merger.

23 43. The disclosures of each of these three trade secrets were made  
24 pursuant to the aforementioned written and/or oral agreements of confidentiality  
25 to SV Life Sciences and New Leaf. On information and belief, these trade secrets  
26 were conveyed to Mr. Wallace and ReShape Medical LLC and SV Health who  
27 each used them for their own benefit.

1           44. A significant portion of the information used by ReShape Medical,  
2 Inc. to design its device and obtain FDA approval constitute Fulfillium trade  
3 secrets in that they: (a) constitute information that derives independent economic  
4 value from not being generally known to the public or to other persons who can  
5 obtain economic value from its disclosure or use; and (b) have been the subject of  
6 reasonable efforts to maintain their secrecy.

7           45. Through SV Life Sciences (SV Health) (and its misappropriation of  
8 Dr. Chen's trade secrets, which were protected via repeated confidentiality  
9 agreements), Mr. Wallace, and Sprout, ReShape Medical LLC and SV Health  
10 acquired confidential, expert validated, trade secret information about all aspects  
11 of Fulfillium's business, including clinical trial design and regulatory strategy.  
12 Specifically, ReShape Medical LLC and SV Health misappropriated at least the  
13 three aforementioned aspects of Dr. Chen and Fulfillium's clinical trial playbook.

14           46. Upon information and belief, ReShape Medical LLC and SV Health  
15 have relied upon and used that trade secret information in some or all aspects of  
16 its business, including raising capital, product design, procedure design, and FDA  
17 clinical trial design.

18           47. The actions alleged above constitute a wrongful misappropriation of  
19 Fulfillium's trade secrets. They also constitute a wrongful conspiracy among the  
20 board directors and officers of and investors in ReShape Medical LLC and SV  
21 Health to misappropriate Fulfillium's trade secrets.

22           48. As a direct and proximate result of the actions alleged above,  
23 Fulfillium has been shut out of the market. By misappropriating Fulfillium's  
24 technology and launching a competing company, ReShape Medical LLC and SV  
25 Health prevented Fulfillium from raising the funds required to bring its product to  
26 market.

27  
28

1           49. As a direct and proximate result of the actions alleged above,  
2 ReShape Medical LLC and SV Health have been unjustly enriched in an amount  
3 no less than the business opportunity deprived from Fulfillium.

4           50. In doing the acts hereinabove alleged, each of ReShape Medical LLC  
5 and SV Health and its investors have engaged in willful and malicious  
6 misappropriation by reason thereof, and Fulfillium is entitled, as against each of  
7 them, to twice the amount of its actual damages and/or the amounts by which  
8 ReShape Medical LLC and SV Health have been unjustly enriched as exemplary  
9 damages pursuant to Civil Code § 3426.3(c) and/or Mass. Gen. Laws ch. 93, § 42-  
10 42A.

11           51. By the aforesaid acts, ReShape Medical LLC and SV Health have  
12 irreparably injured Fulfillium and such injury will continue unless enjoined by this  
13 Court.

14           **COUNT II – INFRINGEMENT OF U.S. PATENT NO. 9,456,915**

15           52. Fulfillium repeats the allegations of paragraphs 1-51 above as though  
16 fully set forth herein.

17           53. On October 4, 2016, U.S. Patent No. 9,456,915 (“the ‘915 patent”),  
18 entitled “Methods, Devices, and Systems for Obesity Treatment,” was duly and  
19 legally issued by the United States Patent and Trademark Office. A true and  
20 correct copy of the ‘915 patent is attached as Exhibit 1.

21           54. Fulfillium is the assignee and owner of the right, title and interest in  
22 and to the ‘915 patent, including the right to assert all causes of action arising  
23 under said patents and the right to any remedies for infringement of them.

24           55. On information and belief, ReShape Medical LLC and ReShape  
25 Lifesciences are engaged in the business of making, using, selling, offering to sell,  
26 and/or importing medical devices. A description of ReShape Medical LLC and  
27 ReShape Lifesciences’ business is available on its business website, which is  
28 located at <http://pro.reshapeready.com>; <https://reshapeready.com/>. A screenshot

1 of the homepage of ReShape Medical LLC’s business website is attached as  
2 Exhibit 3.

3 56. As part of its business, each of ReShape Medical LLC and ReShape  
4 Lifesciences makes, uses, offers to sell, sells, and/or imports a dual intragastric  
5 balloon for weight loss, including ReShape’s “Duo Balloon” device, which is  
6 placed inside the patient’s stomach for weight loss. ReShape Medical LLC and  
7 ReShape Lifesciences have purposefully sold and offered for sale such Duo  
8 Balloon devices throughout the United States.


9 57. Upon information and belief, each of ReShape Medical LLC and  
10 ReShape Lifesciences has and continues to directly infringe at least claims 1-2 and  
11 4-27 of the ‘915 patent by making, using, selling, importing and/or providing and  
12 causing to be used medical devices for weight loss, including but not limited to,  
13 those sold under the name ReShape Duo Balloon (the “Infringing  
14 Instrumentalities” or “ReShape Balloon”). For clarity the terms “Infringing  
15 Instrumentalities” and “ReShape Balloon” are understood to include the balloon  
16 device intended for delivery into the gastric cavity, as well as any delivery system  
17 for that balloon device.

18 58. Representative claim 1 of the ‘915 patent recites a “gastric balloon  
19 structure for deploying in a gastric cavity of a patient, comprising: at least two  
20 isolated non-concentric inflatable chambers, wherein each chamber of the at least  
21 two isolated non-concentric inflatable chambers has a respective inflated state  
22 volume such that deflation of any single chamber of the at least two isolated non-  
23 concentric inflatable chambers leaves the inflated state volume of the remaining  
24 chambers of the at least two isolated non-concentric inflatable chambers  
25 unaffected.” The Infringing Instrumentalities infringe claim 1 of the ‘915 patent.  
26 The ReShape Dual Balloon “is a temporary implant designed to facilitate weight  
27 loss by occupying space in the stomach.” ReShape™ Integrated Dual Balloon  
28 System Instructions for Use, PN 03-0300 Rev. D, p. 1,



1 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
2 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
3 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
4 stomach. The ReShape website states that “[i]n the unlikely event of individual  
5 gastric balloon leakage or deflation, the independently sealed *ReShape* weight loss  
6 balloons are designed to minimize risk of migration or obstruction.”

7 <http://pro.reshapeready.com/about-reshape/#theadvantages>. In other words, each  
8 balloon inflates and deflates independently. *See also*  
9 <https://www.youtube.com/watch?v=U91FsjtMf3o>.




10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
**Figure 1. *ReShape* Dual Balloon in the Stomach**

21 59. Claim 1 further recites “a valve system for introducing a fluid into  
22 the at least two isolated non-concentric inflatable chambers and for retaining,  
23 upon inflation, the fluid in the at least two isolated non-concentric inflatable  
24 chambers.” The chambers of the ReShape balloons are filled after they are  
25 positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon System  
26 Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
27 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
28 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”

1 *Id.*; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>; U.S. Pat. No.  
2 8,142,469 at Fig. 1, 3-5.

3           60. Claim 1 further recites “a flexible central spine spanning a gap  
4 between and fixedly attached to both a first chamber of the at least two isolated  
5 non-concentric inflatable chambers and a second chamber of the at least two  
6 isolated non-concentric inflatable chambers; wherein the gastric balloon structure,  
7 in its inflated state, assumes a curved shape conforming to a natural three-  
8 dimensional kidney shape of the gastric cavity, such that the flexible central spine  
9 flexibly conforms, upon at least partially filling the at least two isolated non-  
10 concentric inflatable chambers, the gastric balloon structure to the natural three-  
11 dimensional kidney shape of the gastric cavity.” The flexible central spine  
12 element is illustrated in the video provided on ReShape’s website, a frame from  
13 which is reproduced below. *See* <https://reshapeready.com/reshape-cc/>; *see also*  
14 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



21 The conformance of the dual balloon to the stomach of the patient is shown in the  
22 image above and is also illustrated in Figure 1 of ReShape’s instructions for use,  
23 reproduced below.




Figure 1. *ReShape* Dual Balloon in the Stomach

61. The final recitation in claim 1 is that “a respective fluid volume for filling each chamber of the at least two isolated non-concentric inflatable chambers is selected based upon dimensions of the gastric cavity of the patient.”

*ReShape*’s instructions for use state as follows:


2.4. Determine the desired inflation volume for each balloon. A fill volume of 375 cc is recommended for patients < 64.5” in stature and 450 cc for patients ≥ 64.5” in stature.

See [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf) at 16. *ReShape* instructs the user to determine the size of the patient and to select a corresponding fill volume for the balloon structure.

62. Claim 2 generally recites the gastric balloon structure of claim 1, wherein the gastric balloon structure is designed to provide for modulated passage of food through the gastric cavity upon inflation.

63. The Infringing Instrumentalities infringe claim 2 of the ‘915 patent. The *ReShape* Dual Balloon “is a temporary implant designed to facilitate weight loss by occupying space in the stomach.” *ReShape*<sup>TM</sup> Integrated Dual Balloon

1 System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
2 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
3 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
4 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
5 stomach providing modulated passage of food through the gastric cavity upon  
6 inflation.



7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19 **Figure 1. ReShape Dual Balloon in the Stomach**


20 64. Claim 4 generally recites the gastric balloon structure of claim 1,  
21 wherein, upon inflation, the gastric balloon structure is configured to rest within  
22 the gastric cavity without exerting pressure at any point in the gastric cavity  
23 sufficient to cause ulceration.

24 65. The Infringing Instrumentalities infringe claim 4 of the ‘915 patent.  
25 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
26 gastric balloon is designed to conform to the patient’s anatomy and enhance  
27 tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
28 Accordingly, on information and belief, it is configured to rest within the gastric

1 cavity without exerting pressure at any point in the gastric cavity sufficient to  
2 cause ulceration.

3 66. Claim 5 generally recites the gastric balloon structure of claim 4,  
4 wherein an outer surface of each of the isolated non-concentric inflatable  
5 chambers is configured to align against greater and lesser curvatures of the gastric  
6 cavity.

7 67. The Infringing Instrumentalities infringe claim 5 of the '915 patent.  
8 The ReShape Dual Balloon mimics "the natural curvature of the stomach, the dual  
9 gastric balloon is designed to conform to the patient's anatomy and enhance  
10 tolerability." See <http://pro.reshapeready.com/about-reshape/#theadvantages>.



11  
12  
13  
14  
15  
16  
17  
18 The conformance of the dual balloon to the stomach of the patient is shown in the  
19 image above and is also illustrated in Figure 1 of ReShape's instructions for use,  
20 reproduced below.





Figure 1. *ReShape* Dual Balloon in the Stomach

Accordingly, on information and belief, an outer surface of each of the isolated non-concentric inflatable chambers is configured to align against greater and lesser curvatures of the gastric cavity.

68. Claim 6 generally recites the gastric balloon structure of claim 1, wherein the valve system comprises a respective valve structure for introducing fluid into each chamber of the at least two isolated non-concentric inflatable chambers, wherein each respective valve structure includes at least two valves in series.

69. Upon information and belief, the Infringing Instrumentalities infringe claim 6 of the '915 patent. The chambers of the *ReShape* balloons are filled after they are positioned in the patient's stomach. *ReShape*<sup>TM</sup> Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). "The *ReShape*<sup>TM</sup> Valve Sealant is necessary to seal the device valves and prevent balloon leakage." *Id.*; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further,

1 ReShape’s patent, U.S. 8,142,469, shows two valves in series as shown below at  
2 206A and 96A:




3 Accordingly, on information and belief, the ReShape Balloon valve system  
4 comprises a respective valve structure for introducing fluid into each chamber of  
5 the two isolated non-concentric inflatable chambers, wherein each respective  
6 valve structure includes at least two valves in series.

7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
70. Claim 7 generally recites the gastric balloon structure of claim 6,  
wherein a first valve structure of a first chamber of the at least two isolated non-  
concentric inflatable chambers includes a one-way valve in series with an  
additional one-way valve.

71. Upon information and belief, the Infringing Instrumentalities infringe  
claim 7 of the ‘915 patent. The chambers of the ReShape balloons are filled after  
they are positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon  
System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17,  
[https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
[content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
*Id.*; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further,

1 ReShape's patent, U.S. 8,142,469, shows two one-way valves in series as shown  
2 below at 206A and 96A:




3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13 Accordingly, on information and belief, the ReShape Balloon valve  
14 structure includes a one-way valve in series with an additional one-way valve.

15 72. Claim 8 generally recites the gastric balloon structure of claim 1,  
16 wherein the flexible central spine is in fluid communication with the valve system.


17 73. Upon information and belief, the Infringing Instrumentalities infringe  
18 claim 8 of the '915 patent. The flexible central spine element is illustrated in the  
19 video provided on ReShape's website, a frame from which is reproduced below.

20 See <https://reshapeready.com/reshape-cc/>; see also  
21 <https://www.youtube.com/watch?v=U91FsjtMf3o>.





1 Further, ReShape’s patent, U.S. 8,142,469, shows that the inflation lumens and  
2 valves are carried by the flexible central spine as shown below:




14 Accordingly, on information and belief, the ReShape Balloon’s flexible  
15 central spine is in fluid communication with the valve system.


16 74. Claim 9 generally recites the gastric balloon structure of claim 8,  
17 wherein the flexible central spine encloses an inflation lumen for introducing the  
18 fluid into the at least two isolated non-concentric inflatable chambers.

19 75. Upon information and belief, the Infringing Instrumentalities infringe  
20 claim 9 of the ‘915 patent. The chambers of the ReShape balloons are filled after  
21 they are positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon  
22 System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17,  
23 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
24 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
25 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
26 *Id.*; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>. The flexible  
27  
28

1 central spine element is illustrated in the video provided on ReShape's website, a  
2 frame from which is reproduced below. See <https://reshapeready.com/reshape-cc/>.



10 Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and  
11 valves are carried by the flexible central spine as shown below:



24 Accordingly, on information and belief, the ReShape Balloon's flexible  
25 central spine encloses an inflation lumen for introducing the fluid into the at least  
26 two isolated non-concentric inflatable chambers.

27 76. Claim 10 generally recites the gastric balloon structure of claim 1,  
28 wherein the gastric balloon structure is designed to maintain the introduced

1 volume of fluid while deployed in the gastric cavity of the patient without  
2 controlled adjustment.

3 77. The Infringing Instrumentalities infringe claim 10 of the ‘915 patent.  
4 The ReShape dual balloons are both filled with saline and remain at a generally  
5 fixed volume until they are removed. *See*  
6 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
7 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
8 15-16, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
9 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf).

10 78. Claim 11 generally recites the gastric balloon structure of claim 1,  
11 wherein each chamber of the at least two isolated non-concentric inflatable  
12 chambers is filled with a same fluid.

13 79. The Infringing Instrumentalities infringe claim 11 of the ‘915 patent.  
14 The ReShape dual balloons are both filled with saline and remain at a fixed  
15 volume until they are removed. *See*  
16 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
17 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
18 15-16.

19 80. Claim 12 recites “a method for treating obesity in a patient,  
20 comprising: measuring one or more dimensions of a gastric cavity of the patient in  
21 a feeding state . . . .” The ReShape Dual Balloon “is a temporary implant  
22 designed to facilitate weight loss by occupying space in the stomach.” ReShape™  
23 Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1.  
24 ReShape’s instructions for use state as follows:

25 2.4. Determine the desired inflation volume for each balloon. A fill volume of  
26 375 cc is recommended for patients < 64.5” in stature and 450 cc for patients ≥  
27 64.5” in stature.  
28

1 See [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
2 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf at 16. ReShape  
3 instructs the user to determine the size of the patient and to select a corresponding  
4 fill volume for the balloon structure.

5 81. Claim 12 further recites “determining, based on the one or more  
6 dimensions of the gastric cavity, a respective fill volume for each chamber of a  
7 plurality of inflatable-space filling chambers of an obesity treatment device . . . .”

8 ReShape’s instructions for use state as follows:

9 2.4. Determine the desired inflation volume for each balloon. A fill volume of  
10 375 cc is recommended for patients < 64.5” in stature and 450 cc for patients ≥  
11 64.5” in stature.

11 See [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
12 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf at 16. ReShape  
13 instructs the user to determine the size of the patient and to select a corresponding  
14 fill volume for the balloon structure.


15 82. Claim 12 further recites “positioning the obesity treatment device in  
16 the gastric cavity in a deflated state . . . .” The chambers of the ReShape balloons  
17 are filled after they are positioned in the patient’s stomach. ReShape™ Integrated  
18 Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17,

19 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
20 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf. “The ReShape™  
21 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”

22 *Id.*

23 83. Claim 12 further recites “after positioning, at least partially filling  
24 each chamber of a plurality of inflatable space-filling chambers of the obesity  
25 treatment device with the respective volume of a same type of fluid via a valve  
26 system, wherein the respective volumes of fluid remain unadjusted during  
27 treatment[.]” The chambers of the ReShape balloons are filled after they are

1 positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon System  
2 Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
3 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The ReShape dual  
4 balloons are both filled with saline and remain at a fixed volume until they are  
5 removed. *See* <https://www.youtube.com/watch?v=U91FsjtMf3o>;  
6 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
7 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
8 15-16. “The ReShape™ Valve Sealant is necessary to seal the device valves and  
9 prevent balloon leakage.” *Id.*; *see also*  
10 <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further, ReShape’s patent,  
11 U.S. 8,142,469, shows two valves in series as shown below at 206A and 96A:



12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 84. Claim 12 further recites “wherein the obesity treatment device  
23 assumes a natural three-dimensional kidney shape of the gastric cavity such that,  
24 upon at least partially filling the chambers, an outer surface of the obesity  
25 treatment device aligns against greater and lesser curvatures of the gastric  
26 cavity . . . .” The conformance of the dual balloon to the stomach of the patient is  
27 shown in the image above and is also illustrated in Figure 1 of ReShape’s  
28 instructions for use, reproduced below.




Figure 1. *ReShape* Dual Balloon in the Stomach

The *ReShape* Dual Balloon mimics “the natural curvature of the stomach, the dual gastric balloon is designed to conform to the patient’s anatomy and enhance tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.

85. Lastly, claim 12 recites “wherein the obesity treatment device, upon at least partially filling the chambers, rests within the gastric cavity without exerting undue pressure against the gastric cavity at any particular point.” The *ReShape* Dual Balloon mimics “the natural curvature of the stomach, the dual gastric balloon is designed to conform to the patient’s anatomy and enhance tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.

86. Claim 13 generally recites the method of claim 12, further comprising, after treating the obesity: (i) deflating, within the gastric cavity, each chamber of the plurality of inflatable space-filling chambers; and (ii) removing the obesity treatment device.

87. The Infringing Instrumentalities infringe claim 13 of the ‘915 patent. Regarding removal and deflation within the gastric cavity, the *ReShape* instructions state “continue aspiration until the proximal balloon is completely

1 deflated.” [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
2 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf, at p. 18. ReShape  
3 Dual Balloons are delivered through endoscopic procedures and “insertion and  
4 removal may be completed in an endoscopy suite.” *See*  
5 <http://pro.reshapeready.com/about-reshape/#theadvantages>.

6 88. Claim 14 generally recites the method of claim 13, wherein removing  
7 the obesity treatment device comprises removing the obesity treatment device via  
8 an esophagus of the patient.

9 89. The Infringing Instrumentalities infringe claim 14 of the ‘915 patent.  
10 ReShape Dual Balloons are removed via endoscopic procedures and “insertion  
11 and removal may be completed in an endoscopy suite.” *See*  
12 <http://pro.reshapeready.com/about-reshape/#theadvantages>.

13 90. Claim 15 generally recites the method of claim 13, wherein deflating  
14 each chamber comprises penetrating each chamber to release the fluid.

15 91. The Infringing Instrumentalities infringe claim 15 of the ‘915 patent.  
16 The ReShape instructions state: “after retracting the needle, advance the catheter  
17 through the cut hole until the balloon surface reaches the triple line marker on the  
18 tubing” and “continue aspiration until the proximal balloon is completely  
19 deflated.” [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
20 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf, at p. 18. In other  
21 words, deflating each chamber comprises penetrating each chamber to release the  
22 fluid.

23 92. Claim 16 generally recites the method of claim 12, wherein  
24 introducing the obesity treatment device inside the gastric cavity comprises  
25 introducing the device though an esophagus of the patient.

26 93. The Infringing Instrumentalities infringe claim 16 of the ‘915 patent.  
27 ReShape Dual Balloons are delivered through endoscopic procedures and  
28

1 “insertion and removal may be completed in an endoscopy suite.” *See*  
2 <http://pro.reshapeready.com/about-reshape/#theadvantages>.

3 94. Claim 17 generally recites the method of claim 12, wherein, upon  
4 inflation, the obesity treatment device rests within the gastric cavity without  
5 exerting pressure at any point in the gastric cavity sufficient to cause ulceration.

6 95. The Infringing Instrumentalities infringe claim 17 of the ‘915 patent.  
7 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
8 gastric balloon is designed to conform to the patient’s anatomy and enhance  
9 tolerability.” *See* <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
10 Accordingly, on information and belief, it is configured to rest within the gastric  
11 cavity without exerting pressure at any point in the gastric cavity sufficient to  
12 cause ulceration.


13 96. Claim 18 generally recites the method of claim 12, wherein at least  
14 partially filling each chamber comprises: (i) releasably attaching an inflation tube  
15 to the valve system; and (ii) introducing the fluid into a first chamber of the  
16 plurality of inflatable space-filling chambers through the inflation tube.

17 97. The Infringing Instrumentalities infringe claim 18 of the ‘915 patent.  
18 The chambers of the ReShape balloons are filled after they are positioned in the  
19 patient’s stomach. ReShape™ Integrated Dual Balloon System Instructions for  
20 Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
21 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
22 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
23 *Id.* at 17. Accordingly, on information and belief, the ReShape balloons are filled  
24 by releasably attaching an inflation tube to the valve system and introducing the  
25 fluid into a first chamber of the inflatable space-filling chambers through the  
26 inflation tube.

27 98. Claim 19 recites “an obesity treatment device for deploying in a  
28 stomach of a patient, comprising: a means for occupying an overall space-filling



1 geometry having or conforming to a natural kidney shape of the stomach, upon  
2 inflation, by aligning an outer surface of the obesity treatment device against  
3 greater and lesser curvatures of the stomach . . . .” The Infringing  
4 Instrumentalities infringe claim 19 of the ‘915 patent. The ReShape Dual Balloon  
5 “is a temporary implant designed to facilitate weight loss by occupying space in  
6 the stomach.” ReShape™ Integrated Dual Balloon System Instructions for Use,  
7 PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
8 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The video on  
9 ReShape’s website shows how the dual balloon structure conforms to the natural  
10 curvature and shape of the stomach. <https://reshapeready.com/reshape-cc/>. A  
11 frame from that video is reproduced below.



12  
13  
14  
15  
16  
17  
18  
19 The conformance of the dual balloon to the stomach of the patient is also  
20 illustrated in Figure 1 of ReShape’s instructions for use, reproduced below.





Figure 1. *ReShape* Dual Balloon in the Stomach

The *ReShape* Dual Balloon mimics “the natural curvature of the stomach, the dual gastric balloon is designed to conform to the patient’s anatomy and enhance tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.

99. Claim 19 further recites “a means for isolating a plurality of inflatable space-filling regions of the overall space-filling geometry such that a collective inflated state volume of the plurality of inflatable space-filling regions remaining inflated after deflation of any single region of the plurality of inflatable space-filling regions prevents the obesity treatment device from passing through a pyloric valve of the stomach . . . .” The introduction of the fluid to the balloons is described at pages 16-17 of the Instructions for Use, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The *ReShape* website states that “[i]n the unlikely event of individual gastric balloon leakage or deflation, the independently sealed *ReShape* weight loss balloons are designed to minimize risk of migration or obstruction.” <http://pro.reshapeready.com/about-reshape/#theadvantages>. In other words, the dual balloon design will prevent the

1 implant from passing to the patient’s intestinal tract in the event one of the  
2 balloons ruptures or otherwise deflates.

3 100. Claim 19 further recites “a means for distributing a fluid to the  
4 plurality of inflatable space-filling regions comprising a first means for receiving  
5 a fluid into a first inflatable space-filling region of the plurality of inflatable  
6 space-filling regions and for retaining the fluid in the first inflatable space-filling  
7 region, and a second means for receiving the fluid into the first inflatable space-  
8 filling region and for retaining the fluid in the first inflatable space-filling region,  
9 wherein the first means is provided in series with the second means . . . .” The  
10 chambers of the ReShape balloons are filled after they are positioned in the  
11 patient’s stomach. ReShape™ Integrated Dual Balloon System Instructions for  
12 Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
13 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The ReShape dual  
14 balloons are both filled with saline and remain at a fixed volume until they are  
15 removed. *See* <https://www.youtube.com/watch?v=U91FsjtMf3o>;  
16 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
17 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
18 15-16. “The ReShape™ Valve Sealant is necessary to seal the device valves and  
19 prevent balloon leakage.” *Id.*; *see also*  
20 <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further, ReShape’s patent,  
21 U.S. 8,142,469, shows two valves in series as shown below at 206A and 96A:



101. Lastly, claim 19 recites “wherein a respective fluid volume for filling each region of the plurality of inflatable space-filling regions to occupy the overall space-filling geometry is selected based upon dimensions of the stomach of the patient.” Reshape’s instructions for use state as follows:


2.4. Determine the desired inflation volume for each balloon. A fill volume of 375 cc is recommended for patients < 64.5” in stature and 450 cc for patients ≥ 64.5” in stature.

See [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf) at 16. ReShape instructs the user to determine the size of the patient and to select a corresponding fill volume for the balloon structure

102. Claim 20 generally recites the obesity treatment device of claim 19, further comprising a means for flexibly connecting at least the first inflatable space-filling region and a second inflatable space-filling region of the plurality of inflatable space-filling regions by spanning a gap between the first inflatable space-filling region and the second inflatable space-filling region, wherein the first inflatable space-filling region is configured to be spaced apart from the

1 second inflatable space-filling region within the stomach along a curved  
2 longitudinal axis of the obesity treatment device.

3 103. The Infringing Instrumentalities infringe claim 20 of the '915 patent.  
4 The ReShape dual balloons use a flexible spine to connect two gastric balloons.  
5 The flexible central spine element is illustrated in the video provided on  
6 ReShape's website, a frame from which is reproduced below. *See*  
7 <https://reshapeready.com/reshape-cc/>; *see also*  
8 <https://www.youtube.com/watch?v=U91FsjtMf3o>.




16 Accordingly, upon information and belief, the ReShape spine flexibly  
17 connects at least the first inflatable space-filling region and a second inflatable  
18 space-filling region of the plurality of inflatable space-filling regions by spanning  
19 a gap between the first inflatable space-filling region and the second inflatable  
20 space-filling region, wherein the first inflatable space-filling region is configured  
21 to be spaced apart from the second inflatable space-filling region within the  
22 stomach along a curved longitudinal axis of the obesity treatment device.


23 104. Claim 21 generally recites the obesity treatment device of claim 20,  
24 wherein the means for flexibly connecting is in fluid communication with the  
25 means for distributing the fluid.

26 105. Upon information and belief, the Infringing Instrumentalities infringe  
27 claim 21 of the '915 patent. The flexible central spine element is illustrated in the  
28 video provided on ReShape's website, a frame from which is reproduced below.

1 See <https://reshapeready.com/reshape-cc/>; see also  
2 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



3  
4  
5  
6  
7  
8  
9  
10 Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and  
11 valves are carried by the flexible central spine as shown below:




12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24 Accordingly, on information and belief, the ReShape balloon's flexible  
25 spine is in fluid communication with the means for distributing the fluid.


26 106. Claim 22 generally recites the obesity treatment device of claim 20,  
27 wherein the means for flexibly connecting is configured to detachably connect,  
28 after deploying in the stomach, to a means for introducing the fluid.

1 107. Upon information and belief, the Infringing Instrumentalities infringe  
2 claim 22 of the '915 patent. The flexible central spine element is illustrated in the  
3 video provided on ReShape's website, a frame from which is reproduced below.

4 See <https://reshapeready.com/reshape-cc/>; see also  
5 <https://www.youtube.com/watch?v=U91FsjtMf3o>.




11 Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and  
12 valves are carried by the flexible central spine as shown below:



23 Accordingly, on information and belief, the ReShape balloon's flexible  
24 spine is configured to detachably connect, after deploying in the stomach, to a  
25 means for introducing the fluid.

1           108. Claim 23 generally recites the obesity treatment device of claim 19,  
2 wherein the means for occupying the overall space-filling geometry provides for  
3 modulated passage of food through the stomach.

4           109. The Infringing Instrumentalities infringe claim 23 of the ‘915 patent.  
5 The ReShape Dual Balloon “is a temporary implant designed to facilitate weight  
6 loss by occupying space in the stomach.” ReShape™ Integrated Dual Balloon  
7 System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
8 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
9 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
10 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
11 stomach providing modulated passage of food through the stomach.





24           **Figure 1. ReShape Dual Balloon in the Stomach**

25           110. Claim 24 generally recites the obesity treatment device of claim 19,  
26 wherein the means for occupying the overall space-filling geometry delineates a  
27 space along a curved longitudinal axis of the obesity treatment device distal to the  
28



1 gastro-esophageal junction for the collection of ingested food and another space  
2 proximal to the pyloric valve for active digestion.

3 111. The Infringing Instrumentalities infringe claim 24 of the '915 patent.  
4 The images below from ReShape's website and instruction manual, found at  
5 <https://reshapeready.com/reshape-cc/> and ReShape™ Integrated Dual Balloon  
6 System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
7 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
8 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), respectively,  
9 demonstrate the geometry required to satisfy this element.



24 **Figure 1. ReShape Dual Balloon in the Stomach**

25 Accordingly, on information and belief, the ReShape Balloon delineates a  
26 space along a curved longitudinal axis of the obesity treatment device distal to the  
27 gastro-esophageal junction for the collection of ingested food and another space  
28 proximal to the pyloric valve for active digestion.



1           112. Claim 25 generally recites the obesity treatment device of claim 19,  
2 wherein the means for occupying the overall space-filling geometry is configured  
3 such that, upon inflation, the obesity treatment device rests within the gastric  
4 cavity without exerting pressure at any point in the stomach sufficient to cause  
5 ulceration.

6           113. The Infringing Instrumentalities infringe claim 25 of the ‘915 patent.  
7 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
8 gastric balloon is designed to conform to the patient’s anatomy and enhance  
9 tolerability.” *See* <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
10 Accordingly, on information and belief, it is configured to rest within the gastric  
11 cavity without exerting pressure at any point in the gastric cavity sufficient to  
12 cause ulceration.

13           114. Claim 26 generally recites the obesity treatment device of claim 19,  
14 wherein the obesity treatment device is configured to be untethered in the stomach  
15 after inflation.

16           115. The Infringing Instrumentalities infringe claim 26 of the ‘915 patent.  
17 The following images below from ReShape’s website and instruction manual  
18 demonstrate that a tether is not used in the ReShape Balloon System. *See*  
19 *generally* <https://reshapeready.com/reshape-cc/>; ReShape™ Integrated Dual  
20 Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
21 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
22 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



**Figure 1. ReShape Dual Balloon in the Stomach**

116. Claim 27 generally recites the obesity treatment device of claim 19, wherein the respective fluid volume of each region of the plurality of inflatable space-filling regions contains a same type of fluid.

117. The Infringing Instrumentalities infringe claim 27 of the '915 patent. The ReShape dual balloons are both filled with saline and remain at a fixed volume until they are removed. *See* <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p. 15-16.

1 118. On information and belief, the Infringing Instrumentalities are used  
2 marketed, provided to, and/or used by or for each of ReShape Medical LLC and  
3 ReShape Lifesciences's partners, clients, customers and end users across the  
4 country and in this District.

5 119. ReShape Medical LLC and ReShape Lifesciences' infringement of  
6 the '915 patent has been, and continues to be knowing, intentional, and willful, in  
7 whole or in part because ReShape Medical, Inc. has been aware of the '915 patent  
8 since its issuance and continue to engage in infringing conduct. ReShape  
9 Medical, Inc. had knowledge of all major aspects of Fulfillium's business plans,  
10 including trade secrets divulged pursuant to an oral agreement of confidentiality.  
11 ReShape Medical, Inc. knew that Fulfillium was actively engaged in patenting its  
12 gastric balloon technology. Further, ReShape Medical, Inc. was fully aware that  
13 its technology would copy many aspects of Dr. Chen's inventions because it was  
14 developed after and with knowledge of Dr. Chen's designs. The fact that  
15 ReShape Medical, Inc. knew of Dr. Chen's patents and believed those patents to  
16 be relevant to ReShape Medical, Inc.'s gastric balloon technology is demonstrated  
17 by ReShape Medical Inc.'s citation of Dr. Chen's patents as relevant prior art  
18 when attempting to procure its own patents. For instance, in December 2012  
19 ReShape Medical, Inc. filed an information disclosure statement with the United  
20 States Patent and Trademark Office indicating that Dr. Chen's previous patent  
21 applications were relevant to ReShape Medical, Inc.'s pending patent application  
22 directed to the ReShape Balloon. Further, outside of their inherited and/or  
23 acquired liability from ReShape Medical, Inc. ReShape Lifesciences and ReShape  
24 Medical LLC have been aware of the '915 patent since at least the time of the  
25 merger, and any further infringement is willful.

26 120. On information and belief, each of ReShape Medical LLC and  
27 ReShape Lifesciences has been aware of the existence of the '915 patent since its  
28 issuance.

1            121. Upon information and belief, since at least the time each of ReShape  
2 Medical LLC and ReShape Lifesciences has been made aware of the ‘915 patent,  
3 each of ReShape Medical LLC and ReShape Lifesciences has induced and  
4 continues to induce others to infringe at least one claim of the ‘915 patent under  
5 35 U.S.C. § 271(b) by, among other things, and with specific intent or willful  
6 blindness, actively aiding and abetting others to infringe, including but not limited  
7 to each ReShape Medical LLC and ReShape Lifesciences’ partners, clients,  
8 customers, and end users, whose use of the Infringing Instrumentalities constitutes  
9 direct infringement of at least one claim of the ‘915 patent.

10            122. In particular, each of ReShape Medical LLC and ReShape  
11 Lifesciences’ actions that aid and abet others such as its partners, customers,  
12 clients, and end users to infringe include advertising and distributing the  
13 Infringing Instrumentalities and providing instruction materials, training, and  
14 services regarding the Infringing Instrumentalities. On information and belief,  
15 each of ReShape Medical LLC and ReShape Lifesciences has engaged in such  
16 actions with specific intent to cause infringement or with willful blindness to the  
17 resulting infringement because each of ReShape Medical LLC and ReShape  
18 Lifesciences has had actual knowledge of the ‘915 patent and knowledge that its  
19 acts were inducing infringement of the ‘915 patent since at least the date each of  
20 ReShape Medical LLC and ReShape Lifesciences received notice that such  
21 activities infringed the ‘915 patent.

22            123. Upon information and belief, each of ReShape Medical LLC and  
23 ReShape Lifesciences is liable as a contributory infringer of the ‘915 patent under  
24 35 U.S.C. § 271(c) by offering to sell, selling and importing into the United States  
25 gastric balloon technology to be especially made or adapted for use in an  
26 infringement of the ‘915 patent. The Infringing Instrumentalities are a material  
27 component for use in practicing the ‘915 patent and are specifically made and are  
28 not a staple article of commerce suitable for substantial non-infringing use.

1 124. Fulfillium has suffered and will continue to suffer damages as a  
2 result of ReShape Medical LLC and ReShape Lifesciences' infringing activities.  
3 On information and belief, each of ReShape Medical LLC and ReShape  
4 Lifesciences has been infringing, and will, unless enjoined by this Court, continue  
5 to infringe the '915 patent by making, using, selling, offering to sell, and/or  
6 importing, at a minimum, its ReShape Duo Balloon.

7 125. Each of ReShape Medical LLC and ReShape Lifesciences' acts of  
8 infringement of the '915 patent have caused and will continue to cause Fulfillium  
9 damages for which Fulfillium is entitled to compensation pursuant to 35 U.S.C. §  
10 284.

11 126. Each of ReShape Medical LLC and ReShape Lifesciences' acts of  
12 infringement of the '915 patent have caused and will continue to cause Fulfillium  
13 immediate and irreparable harm unless such infringing activities are enjoined by  
14 this Court pursuant to 35 U.S.C. § 283. Fulfillium has no adequate remedy at law.

15 127. This case is exceptional and, therefore, Fulfillium is entitled to an  
16 award of attorneys' fees pursuant to 35 U.S.C. § 285.

17 **COUNT III – INFRINGEMENT OF U.S. PATENT NO. 9,445,930**

18 128. Fulfillium repeats the allegations of paragraphs 1-127 above as  
19 though fully set forth herein.

20 129. On September 20, 2016, U.S. Patent No. 9,445,930 ("the '930  
21 patent"), entitled "Methods, Devices, and Systems for Obesity Treatment," was  
22 duly and legally issued by the United States Patent and Trademark Office. A true  
23 and correct copy of the '930 patent is attached as Exhibit 2.

24 130. Fulfillium is the assignee and owner of the right, title and interest in  
25 and to the '930 patent, including the right to assert all causes of action arising  
26 under said patents and the right to any remedies for infringement of them.

27 131. On information and belief, ReShape Medical LLC and ReShape  
28 Lifesciences are engaged in the business of making, using, selling, offering to sell,

1 and/or importing medical devices. A description of ReShape Lifesciences’  
2 business is available on its business website, which is located at  
3 <http://pro.reshapeready.com>; <https://reshapeready.com/>.

4 132. As part of its business, each of ReShape Medical LLC and ReShape  
5 Lifesciences makes, uses, offers to sell, sells, and/or imports a dual intragastric  
6 balloon for weight loss, including ReShape Medical’s “Duo Balloon” device,  
7 which is placed inside the patient’s stomach for weight loss. ReShape Medical  
8 LLC and ReShape Lifesciences have purposefully sold and offered for sale such  
9 Duo Balloon devices throughout the United States.

10 133. Upon information and belief, each of ReShape Medical LLC and  
11 ReShape Lifesciences has and continues to directly infringe at least claims 1-2, 4-  
12 19, 21-27, and 30 of the ‘930 patent by making, using, selling, importing and/or  
13 providing and causing to be used medical devices for weight loss, including but  
14 not limited to, those sold under the name ReShape Duo Balloon (the “Infringing  
15 Instrumentalities”).

16 134. Claim 1 of the ‘930 patent generally recites “An obesity treatment  
17 device for deploying in a stomach of a patient, comprising: a plurality of adjacent,  
18 spaced apart inflatable space-filling compartments, wherein each compartment of  
19 the plurality of inflatable space-filling compartments has a respective inflated state  
20 volume that is maintained during treatment of the patient . . . .” The Infringing  
21 Instrumentalities infringe claim 1 of the ‘930 patent. The ReShape Dual Balloon  
22 “is a temporary implant designed to facilitate weight loss by occupying space in  
23 the stomach.” ReShape™ Integrated Dual Balloon System Instructions for Use,  
24 PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
25 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
26 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
27 stomach. The ReShape website states that “[i]n the unlikely event of individual  
28 gastric balloon leakage or deflation, the independently sealed *ReShape* weight loss

1 balloons are designed to minimize risk of migration or obstruction.”  
2 <http://pro.reshapeready.com/about-reshape/#theadvantages>. In other words, each  
3 balloon inflates and deflates independently and its inflated volume is maintained.  
4 *See also* <https://www.youtube.com/watch?v=U91FsjtMf3o>.





Figure 1. *ReShape* Dual Balloon in the Stomach

13  
14 135. Claim 1 further recites “a valve system for introducing a fluid into  
15 each compartment of the plurality of inflatable space-filling compartments and for  
16 retaining, upon inflation, fluid in the plurality of inflatable space-filling  
17 compartments . . . .” The chambers of the *ReShape* balloons are filled after they  
18 are positioned in the patient’s stomach. *ReShape*<sup>TM</sup> Integrated Dual Balloon  
19 System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17,  
20 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
21 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The *ReShape*<sup>TM</sup>  
22 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
23 *Id.*; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>; U.S. Pat. No.  
24 8,142,469 at Fig. 1, 3-5.


25 136. Claim 1 further recites “the valve system comprises a respective  
26 valve structure for introducing fluid into each inflatable space-filling compartment  
27 of the plurality of inflatable space-filling compartments, wherein each respective  
28 valve structure includes at least a first valve in series with a second valve . . . .”




1 The chambers of the ReShape balloons are filled after they are positioned in the  
2 patient's stomach. ReShape™ Integrated Dual Balloon System Instructions for  
3 Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
4 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
5 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
6 *Id.*; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further,  
7 ReShape's patent, U.S. 8,142,469, shows two valves in series as shown below at  
8 206A and 96A:



10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 137. Lastly, claim 1 recites “wherein the obesity treatment device is to  
22 form, upon at least partially filling the plurality of inflatable space-filling  
23 compartments, to a curved shape conforming to a natural three-dimensional  
24 kidney shape of the stomach such that an outer surface of the obesity treatment  
25 device aligns against greater and lesser curvatures of the stomach.” The video on  
26 ReShape's website shows how the dual balloon structure conforms to the natural  
27 curvature of the stomach. <https://reshapeready.com/reshape-cc/>. A frame from  
28 that video is reproduced below.



7 The conformance of the dual balloon to the stomach of the patient is also  
8 illustrated in Figure 1 of ReShape’s instructions for use, reproduced below.




20 **Figure 1. ReShape Dual Balloon in the Stomach**

21  
22 The ReShape Dual Balloon mimics “the natural curvature of the stomach,  
23 the dual gastric balloon is designed to conform to the patient’s anatomy and  
24 enhance tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
25

26 138. Claim 2 generally recites the obesity treatment device of claim 1,  
27 wherein the plurality of inflatable space-filling compartments form, when in an  
28 inflated state, a cavity therebetween through which food may pass.

1           139. The Infringing Instrumentalities infringe claim 2 of the ‘930 patent.  
2 The ReShape Dual Balloon “is a temporary implant designed to facilitate weight  
3 loss by occupying space in the stomach.” ReShape™ Integrated Dual Balloon  
4 System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
5 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
6 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
7 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
8 stomach forming a cavity through which food may pass upon inflation.



21           **Figure 1. ReShape Dual Balloon in the Stomach**


22           140. Claim 4 generally recites the obesity treatment device of claim 1,  
23 wherein, upon inflation, the obesity treatment device rests within the stomach  
24 without exerting pressure at any point in the stomach sufficient to cause  
25 ulceration.

26           141. The Infringing Instrumentalities infringe claim 4 of the ‘930 patent.  
27 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
28 gastric balloon is designed to conform to the patient’s anatomy and enhance

1 tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
2 Accordingly, on information and belief, it is configured to rest within the gastric  
3 cavity without exerting pressure at any point in the gastric cavity sufficient to  
4 cause ulceration.

5 142. Claim 5 generally recites the obesity treatment device of claim 1,  
6 wherein an outer surface of each of the inflatable space-filling compartments  
7 aligns against greater and lesser curvatures of the stomach.

8 143. The Infringing Instrumentalities infringe claim 5 of the ‘930 patent.  
9 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
10 gastric balloon is designed to conform to the patient’s anatomy and enhance  
11 tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.



18 The conformance of the dual balloon to the stomach of the patient is shown in the  
19 image above and is also illustrated in Figure 1 of ReShape’s instructions for use,  
20 reproduced below.





Figure 1. *ReShape* Dual Balloon in the Stomach

Accordingly, on information and belief, an outer surface of each of the inflatable space filling compartments is configured to align against greater and lesser curvatures of the stomach.

144. Claim 6 generally recites the obesity treatment device of claim 5, wherein the obesity treatment device is untethered in the stomach after inflation.

145. The Infringing Instrumentalities infringe claim 6 of the '930 patent. The following images below from ReShape's website and instruction manual demonstrate that the ReShape Balloon is untethered in the stomach after inflation. See generally <https://reshapeready.com/reshape-cc/>; ReShape™ Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf).







Figure 1. *ReShape* Dual Balloon in the Stomach

146. Claim 7 generally recites the obesity treatment device of claim 1, wherein the first valve structure includes a one-way valve.

147. Upon information and belief, the Infringing Instrumentalities infringe claim 7 of the '930 patent. The chambers of the *ReShape* balloons are filled after they are positioned in the patient's stomach. *ReShape*<sup>TM</sup> Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). "The *ReShape*<sup>TM</sup> Valve Sealant is necessary to seal the device valves and prevent balloon leakage." *Id.*; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further, *ReShape*'s patent, U.S. 8,142,469, shows a one-way valves as shown below at 206A and 96A:




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12 Accordingly, on information and belief, the ReShape Balloon's first valve  
13 structure includes a one-way valve.


14 148. Claim 8 generally recites the obesity treatment device of claim 1,  
15 further comprising a flexible central spine structure spanning a gap between and  
16 connecting at least a first compartment of the plurality of inflatable space-filling  
17 compartments and a second compartment of the plurality of inflatable space-  
18 filling compartments, wherein aligning the outer surface of the obesity treatment  
19 device against the greater and lesser curvatures of the stomach comprises flexibly  
20 conforming the obesity treatment device to the natural three dimensional kidney  
21 shape of the stomach through flexing the flexible central spine structure.

22 149. The Infringing Instrumentalities infringe claim 8 of the '930 patent.  
23 The flexible central spine element is illustrated in the video provided on  
24 ReShape's website, a frame from which is reproduced below. *See*  
25 <https://reshapeready.com/reshape-cc/>; *see also*  
26 <https://www.youtube.com/watch?v=U91FsjtMf3o>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



The conformance of the dual balloon to the stomach of the patient is shown in the image above and is also illustrated in Figure 1 of ReShape’s instructions for use, reproduced below.



**Figure 1. ReShape Dual Balloon in the Stomach**

Accordingly, on information and belief, the ReShape Balloon’s flexible central spine structure spans a gap between and connects at least a first compartment of the plurality of inflatable space-filling compartments and a second compartment of the plurality of inflatable space-filling compartments, wherein aligning the outer surface of the obesity treatment device against the greater and lesser curvatures of the stomach comprises flexibly conforming the




1 obesity treatment device to the natural three dimensional kidney shape of the  
2 stomach through flexing the flexible central spine structure.


3 150. Claim 9 generally recites the obesity treatment device of claim 8,  
4 wherein the flexible central spine structure is in fluid communication with the  
5 valve system.

6 151. Upon information and belief, the Infringing Instrumentalities infringe  
7 claim 9 of the '930 patent. The flexible central spine element is illustrated in the  
8 video provided on ReShape's website, a frame from which is reproduced below.

9 See <https://reshapeready.com/reshape-cc/>; see also  
10 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



11  
12  
13  
14  
15  
16  
17 Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and  
18 valves are carried by the flexible central spine as shown below:




1 Accordingly, on information and belief, the ReShape Balloon's flexible  
2 central spine structure is in fluid communication with the valve system.


3 152. Claim 10 generally recites the obesity treatment device of claim 9,  
4 wherein the flexible central spine structure encloses an inflation lumen for  
5 introducing the fluid into the plurality of inflatable space-filling compartments.

6 153. Upon information and belief, the Infringing Instrumentalities infringe  
7 claim 10 of the '930 patent. The flexible central spine element is illustrated in the  
8 video provided on ReShape's website, a frame from which is reproduced below.

9 See <https://reshapeready.com/reshape-cc/>; see also  
10 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



11  
12  
13  
14  
15  
16  
17 Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and  
18 valves are carried by the flexible central spine as shown below:



1           Accordingly, on information and belief, the ReShape Balloon’s flexible  
2 central spine structure encloses an inflation lumen for introducing the fluid into  
3 the plurality of inflatable space-filling compartments.

4           154. Claim 11 generally recites the obesity treatment device of claim 1,  
5 wherein fluid in each of the plurality of inflatable space-filling compartments is a  
6 same type of fluid.

7           155. The Infringing Instrumentalities infringe claim 11 of the ‘930 patent.  
8 The ReShape dual balloons are both filled with saline and remain at a fixed  
9 volume until they are removed. *See*  
10 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
11 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
12 15-16.

13           156. Claim 12 of the ‘930 patent recites a “method for deploying a gastric  
14 balloon structure in a gastric cavity of a patient.” The ReShape Dual Balloon “is a  
15 temporary implant designed to facilitate weight loss by occupying space in the  
16 stomach.” ReShape™ Integrated Dual Balloon System Instructions for Use, PN  
17 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
18 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
19 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
20 stomach.




Figure 1. *ReShape* Dual Balloon in the Stomach

157. Claim 12 of the ‘930 patent further recites the steps of “determining one or more dimensions of the gastric cavity in a feeding state” and “selecting a respective fill volume for each chamber of a plurality of isolated chambers of the gastric balloon structure.” *Reshape’s* instructions for use state as follows:

2.4. Determine the desired inflation volume for each balloon. A fill volume of 375 cc is recommended for patients < 64.5” in stature and 450 cc for patients ≥ 64.5” in stature.

See [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf) at 16. *ReShape* instructs the user to determine the size of the patient and to select a corresponding fill volume for the balloon structure.


158. Claim 12 further recites “introducing the gastric balloon structure to the gastric cavity; and after said introducing, at least partially filling each chamber of the plurality of isolated chambers of the gastric balloon structure with the respective volume of fluid via a valve system of the gastric balloon structure.”

The chambers of the *ReShape* balloons are filled after they are positioned in the patient’s stomach. *ReShape™* Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The *ReShape™*


1 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
2 *Id.* at 17.

3 159. Claim 12 further recites that “the plurality of isolated chambers are  
4 non-concentric and adjacent, at least partially filling each chamber of the plurality  
5 of isolated chambers comprises introducing fluid into the respective chamber via a  
6 respective valve structure of the valve system, and a collective volume of the  
7 plurality of isolated chambers remaining inflated after deflation of any single  
8 chamber of the plurality of isolated chambers prevents the gastric balloon  
9 structure from passing through the pyloric valve of the gastric cavity.” Figure 1 of  
10 the Instructions for Use shows that the ReShape balloon has two nonconcentric  
11 and adjacent chambers. The introduction of the fluid to the balloons is described  
12 at pages 16-17 of the Instructions for Use, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
13 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The ReShape  
14 website states that “[i]n the unlikely event of individual gastric balloon leakage or  
15 deflation, the independently sealed *ReShape* weight loss balloons are designed to  
16 minimize risk of migration or obstruction.” [http://pro.reshapeready.com/about-](http://pro.reshapeready.com/about-reshape/#theadvantages)  
17 [reshape/#theadvantages](http://pro.reshapeready.com/about-reshape/#theadvantages). In other words, the dual balloon design will prevent the  
18 implant from passing to the patient’s intestinal tract in the event one of the  
19 balloons ruptures.

20 160. Claim 12 further recites that “the gastric balloon structure, in its  
21 inflated state, is to form to a curved shape conforming to a natural three-  
22 dimensional kidney shape of the gastric cavity such that an outer surface of the  
23 gastric balloon structure aligns against greater and lesser curvatures of the gastric  
24 cavity.” The video on ReShape’s website shows how the dual balloon structure  
25 conforms to the natural curvature of the stomach.  
26 <https://reshapeready.com/reshape-cc/>. A frame from that video is reproduced  
27 below.  
28



7 The conformance of the dual balloon to the stomach of the patient is also  
8 illustrated in Figure 1 of ReShape’s instructions for use, reproduced below.



20 **Figure 1. ReShape Dual Balloon in the Stomach**


21 161. Claim 13 generally recites the method of claim 12, wherein the  
22 gastric balloon structure, upon inflation, rests within the gastric cavity without  
23 exerting pressure at any point in the gastric cavity sufficient to cause ulceration.

24 162. The Infringing Instrumentalities infringe claim 13 of the '930 patent.  
25 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
26 gastric balloon is designed to conform to the patient’s anatomy and enhance  
27 tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
28 Accordingly, on information and belief, it is configured to rest within the gastric


1 cavity without exerting pressure at any point in the gastric cavity sufficient to  
2 cause ulceration.

3 163. Claim 14 generally recites the method of claim 12, wherein an outer  
4 surface of each one of the space-filling compartments aligns against greater and  
5 lesser curvatures of the stomach.

6 164. The Infringing Instrumentalities infringe claim 14 of the '930 patent.  
7 The ReShape Dual Balloon mimics "the natural curvature of the stomach, the dual  
8 gastric balloon is designed to conform to the patient's anatomy and enhance  
9 tolerability." See <http://pro.reshapeready.com/about-reshape/#theadvantages>.



16 The conformance of the dual balloon to the stomach of the patient is shown in the  
17 image above and is also illustrated in Figure 1 of ReShape's instructions for use,  
18 reproduced below.



27  
28

Figure 1. ReShape Dual Balloon in the Stomach

1           Accordingly, on information and belief, an outer surface of each of the  
2 space filling compartments is configured to align against greater and lesser  
3 curvatures of the gastric cavity.

4           165. Claim 15 generally recites the method of claim 12, wherein at least  
5 partly filling the plurality of isolated chambers comprises (i) releasably attaching  
6 an inflation tube to the valve system and (ii) introducing the fluid into a first  
7 isolated chamber of the plurality of isolated chambers through the inflation tube.

8           166. The Infringing Instrumentalities infringe claim 15 of the ‘930 patent.  
9 The chambers of the ReShape balloons are filled after they are positioned in the  
10 patient’s stomach. ReShape™ Integrated Dual Balloon System Instructions for  
11 Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
12 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The instructions  
13 state: “Connect the inflation tubing to the proximal balloon fill tube (catheter  
14 lanyard 1) and inflate to the desired volume. Monitor inflation under endoscopic  
15 visualization.” *Id.* at 17. “The ReShape™ Valve Sealant is necessary to seal the  
16 device valves and prevent balloon leakage.” *Id.* at 17. Accordingly, on  
17 information and belief, the ReShape balloons are filled by releasibly attaching an  
18 inflation tube to the valve system and introducing the fluid into a first chamber of  
19 the inflatable space-filling chambers through the inflation tube.

20           167. Claim 16 generally recites the method of claim 12, wherein  
21 introducing the gastric balloon structure to the gastric cavity comprises  
22 introducing the gastric balloon structure through an esophagus of the patient.

23           168. The Infringing Instrumentalities infringe claim 16 of the ‘930 patent.  
24 ReShape Dual Balloons are delivered through endoscopic procedures and  
25 “insertion and removal may be completed in an endoscopy suite.” *See*  
26 <http://pro.reshapeready.com/about-reshape/#theadvantages>.



1           169. Claim 17 generally recites the method of claim 12, wherein a  
2 diameter of the gastric balloon structure is no larger than 2 centimeters prior to  
3 inflation.

4           170. Upon information and belief, the Infringing Instrumentalities infringe  
5 claim 17 of the ‘930 patent. *See* ReShape™ Integrated Dual Balloon System  
6 Instructions for Use, PN 03-0300 Rev. D, pp. 2, 16-17,  
7 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
8 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf).

9           171. Claim 18 generally recites the method of claim 12, wherein fluid in  
10 each of the plurality of isolated chambers is a same type of fluid.

11           172. The Infringing Instrumentalities infringe claim 18 of the ‘930 patent.  
12 The ReShape dual balloons are both filled with saline and remain at a fixed  
13 volume until they are removed. *See*  
14 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
15 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
16 15-16.

17           173. Claim 19 recites “a system for treating obesity, comprising: a means  
18 for conforming a flexible, space-filling structure to a natural kidney shape of a  
19 gastric cavity of a patient . . . .” The Infringing Instrumentalities infringe claim 19  
20 of the ‘930 patent. The ReShape Dual Balloon “is a temporary implant designed  
21 to facilitate weight loss by occupying space in the stomach.” ReShape™  
22 Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
23 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
24 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
25 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
26 stomach.



Figure 1. *ReShape* Dual Balloon in the Stomach

The *ReShape* Dual Balloon mimics “the natural curvature of the stomach, the dual gastric balloon is designed to conform to the patient’s anatomy and enhance tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.

174. Claim 19 further recites “a means for maintaining at least two isolated inflatable regions of the flexible, space-filling structure such that a collective volume of the at least two isolated inflatable regions remaining inflated after deflation of any single isolated inflatable region of the at least two isolated inflatable regions prevents the flexible, space-filling structure from passing through the pylorus of the patient . . . .” Figure 1 of the Instructions for Use shows that the *ReShape* balloon has two nonconcentric and adjacent chambers. The introduction of the fluid to the balloons is described at pages 16-17 of the Instructions for Use, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The *ReShape* website states that “[i]n the unlikely event of individual gastric balloon leakage or deflation, the independently sealed *ReShape* weight loss balloons are designed to minimize risk of migration or obstruction.” <http://pro.reshapeready.com/about-reshape/#theadvantages>. In other words, the dual balloon design will prevent the implant from passing to the patient’s intestinal tract in the event one of the balloons ruptures.


1           175. Claim 19 further recites “a means for introducing a fluid into each of  
2 the at least two isolated inflatable regions after positioning the flexible, space-  
3 filling structure within the gastric cavity, wherein the means for introducing is  
4 configured to be separated from said means for conforming after introducing the  
5 fluid . . . .” The chambers of the ReShape balloons are filled after they are  
6 positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon System  
7 Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
8 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
9 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
10 *Id.* at 17.

11           176. Lastly, claim 19 recites “a means for receiving the fluid into each  
12 region of the at least two isolated inflatable regions and for retaining the fluid in  
13 each region, wherein the fluid is received from the means for introducing the  
14 fluid.” The chambers of the ReShape balloons are filled after they are positioned  
15 in the patient’s stomach. ReShape™ Integrated Dual Balloon System Instructions  
16 for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
17 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
18 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
19 *Id.* at 17.

20           177. Claim 21 generally recites the system of claim 19, wherein the means  
21 for conforming provides for modulated passage of food through the gastric cavity.

22           178. The Infringing Instrumentalities infringe claim 21 of the ‘930 patent.  
23 The ReShape Dual Balloon “is a temporary implant designed to facilitate weight  
24 loss by occupying space in the stomach.” ReShape™ Integrated Dual Balloon  
25 System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
26 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
27 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below,  
28

1 taken from ReShape’s instruction manual, shows the dual balloon in a patient’s  
2 stomach providing modulated passage of food through the gastric cavity.



3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13 **Figure 1. ReShape Dual Balloon in the Stomach**

14 179. Claim 22 generally recites the system of claim 19, wherein the means  
15 for conforming is configured such that, upon inflation, the flexible space-filling  
16 structure rests within the gastric cavity without exerting pressure at any point in  
17 the gastric cavity sufficient to cause ulceration.

18 180. The Infringing Instrumentalities infringe claim 22 of the ‘930 patent.  
19 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
20 gastric balloon is designed to conform to the patient’s anatomy and enhance  
21 tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
22 Accordingly, on information and belief, it is configured to rest within the gastric  
23 cavity without exerting pressure at any point in the gastric cavity sufficient to  
24 cause ulceration.

25 181. Claim 23 generally recites the system of claim 22, wherein undue  
26 pressure against the gastric cavity is avoided in part through at least one of i) a fill  
27 weight of collective volumes of the at least two isolated inflatable regions, ii) a  
28 distribution of the overall space-filling structure, and iii) a buoyancy of the fluid.

1           182. The Infringing Instrumentalities infringe claim 23 of the ‘930 patent.  
2 The ReShape Balloon prevents undue pressure through a fill weight of collective  
3 volumes of the at least two isolated inflatable regions. ReShape’s instructions for  
4 use state as follows:

5           2.4. Determine the desired inflation volume for each balloon. A fill volume of  
6           375 cc is recommended for patients < 64.5” in stature and 450 cc for patients ≥  
7           64.5” in stature.

8 *See* [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
9 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf) at 16. ReShape  
10 instructs the user to determine the size of the patient and to select a corresponding  
11 fill volume for the balloon structure. Further, the ReShape Dual Balloon prevents  
12 undue pressure through a distribution of the overall space-filling structure in that it  
13 mimics “the natural curvature of the stomach, the dual gastric balloon is designed  
14 to conform to the patient’s anatomy and enhance tolerability.” *See*  
15 <http://pro.reshapeready.com/about-reshape/#theadvantages>.


16           183. Claim 24 generally recites the system of claim 19, wherein the means  
17 for receiving the fluid comprises a respective valve structure of each region of the  
18 at least two isolated inflatable regions, the respective valve structure comprising at  
19 least a first valve and a second valve.

20           184. Upon information and belief, the Infringing Instrumentalities infringe  
21 claim 24 of the ‘930 patent. The chambers of the ReShape balloons are filled after  
22 they are positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon  
23 System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17,  
24 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
25 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). Each of the two  
26 balloons in the ReShape Balloon are filled through a valve system as  
27 demonstrated by the instructional videos and instruction manual, which states  
28 “[t]he ReShape™ Valve Sealant is necessary to seal the device valves and prevent

1 balloon leakage.” *Id.*; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>;  
2 <http://pro.reshapeready.com/about-reshape/> (providing an in-patient medical  
3 instructional video about placement, inflation, and removal of the ReShape  
4 Balloon). Accordingly, on information and belief, the ReShape Balloon valves  
5 comprise a respective valve structure of each region of the at least two isolated  
6 inflatable regions, the respective valve structure comprising at least a first valve  
7 and a second valve.

8 185. Claim 25 generally recites the system of claim 19, further comprising  
9 a means for flexibly connecting at least a first region of the at least two isolated  
10 inflatable regions and a second region of the at least two isolated inflatable  
11 regions by spanning a gap between the first region and the second region, thereby  
12 forming a cavity between the first region and the second region through which  
13 food may pass.

14 186. The Infringing Instrumentalities infringe claim 25 of the ‘930 patent.  
15 The flexible central spine element is illustrated in the video provided on  
16 ReShape’s website, a frame from which is reproduced below. *See*  
17 <https://reshapeready.com/reshape-cc/>; *see also*  
18 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



25 The conformance of the dual balloon to the stomach of the patient is shown in the  
26 image above and is also illustrated in Figure 1 of ReShape’s instructions for use,  
27 reproduced below.





Figure 1. *ReShape* Dual Balloon in the Stomach

Accordingly, on information and belief, the ReShape Balloon's spine flexibly connects at least a first region of the at least two isolated inflatable regions and a second region of the at least two isolated inflatable regions by spanning a gap between the first region and the second region, thereby forming a cavity between the first region and the second region through which food may pass.


187. Claim 26 generally recites the system of claim 25, wherein the means for flexibly connecting at least the first isolated inflatable region and the second isolated inflatable region is in fluid communication with the means for receiving the fluid.

188. Upon information and belief, the Infringing Instrumentalities infringe claim 26 of the '930 patent. The flexible central spine element is illustrated in the video provided on ReShape's website, a frame from which is reproduced below.

See <https://reshapeready.com/reshape-cc/>; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>.



Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and valves are carried by the flexible central spine as shown below:




Accordingly, on information and belief, the ReShape Balloon's spine is in fluid communication with the means for receiving the fluid.


189. Claim 27 generally recites the system of claim 25, wherein the means for flexibly connecting comprises a flexible central spine.

190. The Infringing Instrumentalities infringe claim 27 of the '930 patent. The flexible central spine element is illustrated in the video provided on ReShape's website, a frame from which is reproduced below. See <https://reshapeready.com/reshape-cc/>; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>.





7 The conformance of the dual balloon to the stomach of the patient is shown in the  
8 image above and is also illustrated in Figure 1 of ReShape’s instructions for use,  
9 reproduced below.



20 **Figure 1. ReShape Dual Balloon in the Stomach**

21 191. Claim 30 generally recites the system of claim 19, wherein fluid in  
22 each of the at least two isolated inflatable regions is a same type of fluid.

23 192. The Infringing Instrumentalities infringe claim 30 of the ‘930 patent.  
24 The ReShape dual balloons are both filled with saline and remain at a fixed  
25 volume until they are removed. *See*  
26 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
27 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf), Sec. 2.1 – 2.7 at p.  
28 15-16.

1           193. On information and belief, the Infringing Instrumentalities are used  
2 marketed, provided to, and/or used by or for each of ReShape Medical LLC and  
3 ReShape Lifesciences' partners, clients, customers and end users across the  
4 country and in this District.

5           194. On information and belief, each of ReShape Medical LLC and  
6 ReShape Lifesciences has been aware of the existence of the '930 patent since its  
7 issuance.

8           195. On information and belief, since at least the time each of ReShape  
9 Medical LLC and ReShape Lifesciences has been aware of the '930 patent, it has  
10 induced and continues to induce others to infringe at least one claim of the '930  
11 patent under 35 U.S.C. § 271(b) by, among other things, and with specific intent  
12 or willful blindness, actively aiding and abetting others to infringe, including but  
13 not limited to each of ReShape Medical LLC and ReShape Lifesciences' partners,  
14 clients, customers, and end users, whose use of the ReShape Medical Duo Balloon  
15 constitutes direct infringement of at least one claim of the '930 patent.

16           196. In particular, each of ReShape Medical LLC and ReShape  
17 Lifesciences' actions that aid and abet others such as its partners, customers,  
18 clients, and end users to infringe include advertising and distributing the ReShape  
19 Medical Duo Balloon, and providing instruction materials, training, and services  
20 regarding the ReShape Medical Duo Balloon. On information and belief, each of  
21 ReShape Medical LLC and ReShape Lifesciences has engaged in such actions  
22 with specific intent to cause infringement or with willful blindness to the resulting  
23 infringement because, on information and belief, it has had actual knowledge of  
24 the '930 patent and knowledge that its acts were inducing infringement of the '930  
25 patent since at least the date the '930 patent issued.

26           197. Upon information and belief, each of ReShape Medical LLC and  
27 ReShape Lifesciences is liable as a contributory infringer of the '930 patent under  
28 35 U.S.C. § 271(c) by offering to sell, selling and importing into the United States

1 gastric balloon technology to be especially made or adapted for use in an  
2 infringement of the '930 patent. The Infringing Instrumentalities are a material  
3 component for use in practicing the '930 patent and are specifically made and are  
4 not a staple article of commerce suitable for substantial non-infringing use.

5 198. ReShape Medical LLC and ReShape Lifesciences' infringement of  
6 the '930 patent has been, and continues to be knowing, intentional, and willful, in  
7 whole or in part because ReShape Medical, Inc. has been aware of the '930 patent  
8 since its issuance and continue to engage in infringing conduct. ReShape  
9 Medical, Inc. had knowledge of all major aspects of Fulfillium's business plans,  
10 including trade secrets divulged pursuant to an oral agreement of confidentiality.  
11 ReShape Medical, Inc. knew that Fulfillium was actively engaged in patenting its  
12 gastric balloon technology. Further, ReShape Medical, Inc. was fully aware that  
13 its technology would copy many aspects of Dr. Chen's inventions because it was  
14 developed after and with knowledge of Dr. Chen's designs. The fact that  
15 ReShape Medical, Inc. knew of Dr. Chen's patents and believed those patents to  
16 be relevant to ReShape Medical, Inc.'s gastric balloon technology is demonstrated  
17 by ReShape Medical, Inc.'s citation of Dr. Chen's patents as relevant prior art  
18 when attempting to procure its own patents. For instance, in December 2012  
19 ReShape Medical, Inc. filed an information disclosure statement with the United  
20 States Patent and Trademark Office indicating that Dr. Chen's previous patent  
21 applications were relevant to ReShape Medical, Inc.'s pending patent application  
22 directed to the ReShape Balloon. Further, outside of their inherited and/or  
23 acquired liability from ReShape Medical, Inc., ReShape Lifesciences and  
24 ReShape LLC have been aware of the '930 patent since at least the time of the  
25 merger, and any further infringement is willful.

26 199. Each of ReShape Medical LLC and ReShape Lifesciences' acts of  
27 infringement of the '930 patent have caused and will continue to cause Fulfillium  
28

1 damages for which Fulfillium is entitled to compensation pursuant to 35 U.S.C. §  
2 284.

3 200. Each of ReShape Medical LLC and ReShape Lifesciences' acts of  
4 infringement of the '930 patent have caused and will continue to cause Fulfillium  
5 immediate and irreparable harm unless such infringing activities are enjoined by  
6 this Court pursuant to 35 U.S.C. § 283. Fulfillium has no adequate remedy at law.

7 201. This case is exceptional and, therefore, Fulfillium is entitled to an  
8 award of attorneys' fees pursuant to 35 U.S.C. § 285.

9 **COUNT IV – INFRINGEMENT OF U.S. PATENT NO. 9,808,367**

10 202. Fulfillium repeats the allegations of paragraphs 1-200 above as  
11 though fully set forth herein.

12 203. On November 7, 2017, U.S. Patent No. 9,808,367 (“the ‘367  
13 patent”), entitled “Methods, Devices, and Systems for Obesity Treatment,” was  
14 duly and legally issued by the United States Patent and Trademark Office. A true  
15 and correct copy of the '367 patent is attached as Exhibit 4.

16 204. Fulfillium is the assignee and owner of the right, title and interest in  
17 and to the '367 patent, including the right to assert all causes of action arising  
18 under said patents and the right to any remedies for infringement of them.

19 205. On information and belief, each of ReShape Medical LLC and  
20 ReShape Lifesciences is engaged in the business of making, using, selling,  
21 offering to sell, and/or importing medical devices. A description of ReShape  
22 Lifesciences' business is available on its business website, which is located at  
23 <http://pro.reshapeready.com>; <https://reshapeready.com/>.



24 206. As part of its business, each of ReShape Medical LLC and ReShape  
25 Lifesciences makes, uses, offers to sell, sells, and/or imports a dual intragastric  
26 balloon for weight loss, including ReShape Medical's “Duo Balloon” device,  
27 which is placed inside the patient's stomach for weight loss. ReShape Medical  
28

1 LLC and ReShape Lifesciences have purposefully sold and offered for sale such  
2 Duo Balloon devices throughout the United States.

3 207. Upon information and belief, each of ReShape Medical LLC and  
4 ReShape Lifesciences has and continues to directly infringe at least claims 1-2, 4-  
5 7, 11-12, and 16-21 of the ‘367 patent by making, using, selling, importing and/or  
6 providing and causing to be used medical devices for weight loss, including but  
7 not limited to, those sold under the name ReShape Duo Balloon (the “Infringing  
8 Instrumentalities”).

9 208. Representative claim 1 of the ‘367 patent recites a “free floating,  
10 untethered gastric balloon structure for deploying in a gastric cavity of a patient,  
11 comprising: at least two isolated non-concentric inflatable chambers, wherein each  
12 chamber of the at least two isolated non-concentric inflatable chambers has a  
13 respective inflated state volume such that deflation of any single chamber of the at  
14 least two isolated non-concentric inflatable chambers leaves the inflated state  
15 volume of the remaining chambers of the at least two isolated non-concentric  
16 inflatable chambers unaffected[.]” The Infringing Instrumentalities infringe claim  
17 1 of the ‘367 patent. The ReShape Dual Balloon “is a temporary implant designed  
18 to facilitate weight loss by occupying space in the stomach.” ReShape™  
19 Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1,  
20 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
21 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf); *see also*  
22 <https://reshapeready.com/reshape-cc/>. The figures below, taken from ReShape’s  
23 instruction manual and documentation, show the dual balloon untethered in a  
24 patient’s stomach. The ReShape website states that “[i]n the unlikely event of  
25 individual gastric balloon leakage or deflation, the independently sealed *ReShape*  
26 weight loss balloons are designed to minimize risk of migration or obstruction.”  
27 <http://pro.reshapeready.com/about-reshape/#theadvantages>. In other words, each  
28

1 balloon inflates and deflates independently. *See also*  
2 <https://www.youtube.com/watch?v=U91FsjtMf3o>.




16 **Figure 1. ReShape Dual Balloon in the Stomach**


17 209. Claim 1 further recites “a valve system for introducing a fluid into  
18 the at least two isolated non-concentric inflatable chambers and for retaining,  
19 upon inflation, the fluid in the at least two isolated non-concentric inflatable  
20 chambers.” The chambers of the ReShape balloons are filled after they are  
21 positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon System  
22 Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
23 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™  
24 Valve Sealant is necessary to seal the device valves and prevent balloon leakage.”  
25 *Id.*; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>; U.S. Pat. No.  
26 8,142,469 at Fig. 1, 3-5.

27 210. Claim 1 further recites “a flexible member spanning a gap between  
28 and fixedly attached to both a first chamber of the at least two isolated non-


1 concentric inflatable chambers and a second chamber of the at least two isolated  
2 non-concentric inflatable chambers, said flexible member carrying inflation tubes  
3 that are in fluid communication with the at least two isolated non-concentric  
4 inflatable chambers; wherein the gastric balloon structure is configured to float  
5 freely in the patient's gastric cavity and is not connected to any catheter, lumen or  
6 tether after deployment in the patient's gastric cavity[.]” The flexible member  
7 element is illustrated in the video provided on ReShape's website, a frame from  
8 which is reproduced below. *See* <https://reshapeready.com/reshape-cc/>; *see also*  
9 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



10  
11  
12  
13  
14  
15  
16  
17 Upon information and belief, the flexible member of the dual balloon carries  
18 inflation tubes that are in fluid communication with the two isolated non-  
19 concentric inflatable chambers. The flexible member element is illustrated in the  
20 video provided on ReShape's website, a frame from which is reproduced below.  
21 *See* <https://reshapeready.com/reshape-cc/>; *see also*  
22 <https://www.youtube.com/watch?v=U91FsjtMf3o>.



Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and valves are carried by the flexible member as shown below:



Accordingly, on information and belief, the ReShape balloon's flexible member is in fluid communication with the means for distributing the fluid. The following images below from ReShape's website and instruction manual demonstrate that a tether is not used in the ReShape Balloon System. *See generally* <https://reshapeready.com/reshape-cc/>; ReShape™ Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf).



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28





Figure 1. *ReShape* Dual Balloon in the Stomach

211. The final recitation in claim 1 recites “wherein the gastric balloon structure, in its inflated state, assumes a curved shape conforming to a natural three dimensional kidney shape of the gastric cavity, such that the flexible member flexibly conforms, upon at least partially filling the at least two isolated non-concentric inflatable chambers, the gastric balloon structure to the natural three-dimensional kidney shape of the gastric cavity.” The conformance of the dual balloon to the stomach of the patient is shown in the image above and is also illustrated in Figure 1 of *ReShape*’s instructions for use, reproduced below.




Figure 1. *ReShape* Dual Balloon in the Stomach

212. Claim 2 generally recites the gastric balloon structure of claim 1, wherein the gastric balloon structure is configured to provide for modulated passage of food through the gastric cavity upon inflation.

213. The Infringing Instrumentalities infringe claim 2 of the ‘367 patent. The *ReShape* Dual Balloon “is a temporary implant designed to facilitate weight loss by occupying space in the stomach.” *ReShape*<sup>TM</sup> Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The figure below, taken from *ReShape*’s instruction manual, shows the dual balloon in a patient’s stomach providing modulated passage of food through the gastric cavity upon inflation.






Figure 1. *ReShape* Dual Balloon in the Stomach

214. Claim 4 generally recites the gastric balloon structure of claim 1, wherein the flexible member is in fluid communication with the valve system.

215. Upon information and belief, the Infringing Instrumentalities infringe claim 4 of the '367 patent. The flexible member element is illustrated in the video provided on ReShape's website, a frame from which is reproduced below. *See* <https://reshapeready.com/reshape-cc/>; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>.




Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and valves are carried by the flexible member as shown below:




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13 Accordingly, on information and belief, the ReShape Balloon's flexible member is  
14 in fluid communication with the valve system.

15 216. Claim 5 generally recites the gastric balloon structure of claim 4,  
16 wherein the flexible member encloses an inflation lumen for introducing the fluid  
17 into the at least two isolated non-concentric inflatable chambers.

18 217. Upon information and belief, the Infringing Instrumentalities infringe  
19 claim 5 of the '367 patent. The chambers of the ReShape balloons are filled after  
20 they are positioned in the patient's stomach. ReShape™ Integrated Dual Balloon  
21 System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17,  
22 [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
23 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). "The ReShape™  
24 Valve Sealant is necessary to seal the device valves and prevent balloon leakage."  
25 *Id.*; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>. The flexible  
26 member element is illustrated in the video provided on ReShape's website, a  
27 frame from which is reproduced below. See <https://reshapeready.com/reshape-cc/>.



Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and valves are carried by the flexible member as shown below:



Accordingly, on information and belief, the ReShape Balloon's flexible member encloses an inflation lumen for introducing the fluid into the at least two isolated non-concentric inflatable chambers.

218. Claim 6 generally recites the gastric balloon structure of claim 1, wherein the gastric balloon structure is configured to maintain the inflated state volume of each of the at least two isolated non-concentric inflatable chambers while deployed in the gastric cavity of the patient without controlled adjustment.

219. The Infringing Instrumentalities infringe claim 6 of the '367 patent. The ReShape dual balloons are both filled with saline and remain at a generally fixed volume until they are removed. *See*

1 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
2 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf, Sec. 2.1 – 2.7 at p.  
3 15-16, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
4 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf.

5 220. Claim 7 generally recites the gastric balloon structure of claim 1,  
6 wherein each chamber of the at least two isolated non-concentric inflatable  
7 chambers is filled with a same fluid.

8 221. The Infringing Instrumentalities infringe claim 7 of the ‘367 patent.  
9 The ReShape dual balloons are both filled with saline and remain at a fixed  
10 volume until they are removed. *See*


11 <https://www.youtube.com/watch?v=U91FsjtMf3o>; [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
12 content/uploads/2015/07/ReShape\_Instructions\_For\_Use.pdf, Sec. 2.1 – 2.7 at p.  
13 15-16.

14 222. Claim 11 generally recites the gastric balloon structure of claim 1,  
15 wherein, upon inflation, the gastric balloon structure is configured to rest within  
16 the gastric cavity without exerting pressure at any point in the gastric cavity  
17 sufficient to cause abrasion, pressure induced lesions, or other trauma.


18 223. The Infringing Instrumentalities infringe claim 11 of the ‘367 patent.  
19 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
20 gastric balloon is designed to conform to the patient’s anatomy and enhance  
21 tolerability.” *See* <http://pro.reshapeready.com/about-reshape/#theadvantages>.  
22 Accordingly, on information and belief, it is configured to rest within the gastric  
23 cavity without exerting pressure at any point in the gastric cavity sufficient to  
24 cause abrasion, pressure induced lesions, or other trauma.

25 224. Claim 12 generally recites the gastric balloon structure of claim 11,  
26 wherein an outer surface of each of the isolated non-concentric inflatable  
27 chambers is configured to align against greater and lesser curvatures of the gastric  
28 cavity.

1           225. The Infringing Instrumentalities infringe claim 12 of the ‘367 patent.  
2 The ReShape Dual Balloon mimics “the natural curvature of the stomach, the dual  
3 gastric balloon is designed to conform to the patient’s anatomy and enhance  
4 tolerability.” See <http://pro.reshapeready.com/about-reshape/#theadvantages>.




11  
12 The conformance of the dual balloon to the stomach of the patient is shown in the  
13 image above and is also illustrated in Figure 1 of ReShape’s instructions for use,  
14 reproduced below.



24 **Figure 1. *ReShape* Dual Balloon in the Stomach**

25 Accordingly, on information and belief, an outer surface of each of the isolated  
26 non-concentric inflatable chambers is configured to align against greater and  
27 lesser curvatures of the gastric cavity.

1           226. Claim 16 of the ‘367 patent generally recites “An obesity treatment  
2 system for deployment in a stomach of a patient such that the system is free-  
3 floating and untethered after deployment, comprising: a plurality of adjacent, non-  
4 concentric, spaced apart inflatable space-filling compartments, wherein each  
5 compartment of the plurality of inflatable space-filling compartments has a  
6 respective inflated state volume during treatment of the patient[.]” The Infringing  
7 Instrumentalities infringe claim 16 of the ‘367 patent. The ReShape Dual Balloon  
8 “is a temporary implant designed to facilitate weight loss by occupying space in  
9 the stomach.” ReShape™ Integrated Dual Balloon System Instructions for Use,  
10 PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf)  
11 [content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf); *see also*  
12 <https://reshapeready.com/reshape-cc/>. The figures below, taken from ReShape’s  
13 instruction manual and documentation, show the dual balloon untethered in a  
14 patient’s stomach. The ReShape website states that “[i]n the unlikely event of  
15 individual gastric balloon leakage or deflation, the independently sealed *ReShape*  
16 weight loss balloons are designed to minimize risk of migration or obstruction.”  
17 <http://pro.reshapeready.com/about-reshape/#theadvantages>. In other words, each  
18 balloon inflates and deflates independently and its inflated volume is maintained.  
19 *See also* <https://www.youtube.com/watch?v=U91FsjtMf3o>.









Figure 1. ReShape Dual Balloon in the Stomach

227. Claim 16 further recites “at least two valves to introduce at least one fluid into each of the plurality of inflatable space-filling compartments and to retain, after inflation, fluid in the plurality of inflatable space-filling compartments[.]” The chambers of the ReShape balloons are filled after they are positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). “The ReShape™ Valve Sealant is necessary to seal the device valves and prevent balloon leakage.” *Id.*; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>; U.S. Pat. No. 8,142,469 at Fig. 1, 3-5.


228. Claim 16 further recites “wherein each valve is a one-way valve and wherein at least one of the at least two valves has a proximal end configured to removably attach to an inflation tube[.]” The chambers of the ReShape balloons are filled after they are positioned in the patient’s stomach. ReShape™ Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, pp. 16-17, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf). The instructions state: “Connect the inflation tubing to the proximal balloon fill tube (catheter

lanyard 1) and inflate to the desired volume. Monitor inflation under endoscopic visualization.” *Id.* at 17. “The ReShape™ Valve Sealant is necessary to seal the device valves and prevent balloon leakage.” *Id.*; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>; Further, ReShape’s patent, U.S. 8,142,469, shows a one-way valves as shown below at 206A and 96A:




Accordingly, on information and belief, the each valve of the ReShape Balloon is a one-way valve and at least one of the at least two valves has a proximal end configured to removably attach to an inflation tube.

229. Claim 16 further recites “wherein the plurality of inflatable space-filling compartments form, upon at least partially filling the plurality of inflatable space-filling compartments, a dual balloon system that is configured to float within the stomach; wherein the dual-balloon system is configured to float freely in the patient’s stomach and is not connected to any catheter, lumen or tether after deployment in the patient’s stomach[.]” The video on ReShape’s website shows how the dual balloon structure floats within the stomach without use of a catheter, lumen or other tether. <https://reshapeready.com/reshape-cc/>. A frame from that video is reproduced below.



1  
2  
3  
4  
5  
6  
7  
8 The ability of the dual balloon to float within the stomach of the patient without a  
9 tether is also illustrated in Figure 1 of ReShape’s instructions for use, reproduced  
10 below.




11  
12  
13  
14  
15  
16  
17  
18  
19 **Figure 1. ReShape Dual Balloon in the Stomach**

20 230. Lastly, claim 16 recites “wherein, upon inflation, the dual balloon  
21 system is configured to float within the stomach without exerting pressure at any  
22 point in the stomach sufficient to cause abrasion, pressure induced lesions, or  
23 other trauma.” The ReShape Dual Balloon mimics “the natural curvature of the  
24 stomach, the dual gastric balloon is designed to conform to the patient’s anatomy  
25 and enhance tolerability.” See [http://pro.reshapeready.com/about-](http://pro.reshapeready.com/about-reshape/#theadvantages)  
26 [reshape/#theadvantages](http://pro.reshapeready.com/about-reshape/#theadvantages). Accordingly, on information and belief, it is configured  
27 to rest within the gastric cavity without exerting pressure at any point in the  
28

1 gastric cavity sufficient to cause abrasion, pressure induced lesions, or other  
2 trauma.

3 231. Claim 17 generally recites the obesity treatment system of claim 16,  
4 wherein an outer surface of each of the inflatable space-filling compartments  
5 abuts a greater or lesser curvature of the stomach.

6 232. The Infringing Instrumentalities infringe claim 17 of the '367 patent.  
7 The ReShape Dual Balloon mimics "the natural curvature of the stomach, the dual  
8 gastric balloon is designed to conform to the patient's anatomy and enhance  
9 tolerability." See <http://pro.reshapeready.com/about-reshape/#theadvantages>.



17 The conformance of the dual balloon to the stomach of the patient is shown in the  
18 image above and is also illustrated in Figure 1 of ReShape's instructions for use,  
19 reproduced below.






Figure 1. *ReShape* Dual Balloon in the Stomach

Accordingly, on information and belief, an outer surface of each of the inflatable space filling compartments abuts a greater or lesser curvature of the stomach.

233. Claim 18 generally recites the obesity treatment system of claim 16, wherein the plurality of inflatable space-filling compartments are untethered in the stomach after inflation.

234. The Infringing Instrumentalities infringe claim 18 of the '367 patent. The following images below from ReShape's website and instruction manual demonstrate that the ReShape Balloon is untethered in the stomach after inflation. See generally <https://reshapeready.com/reshape-cc/>; ReShape™ Integrated Dual Balloon System Instructions for Use, PN 03-0300 Rev. D, p. 1, [https://reshapeready.com/wp-content/uploads/2015/07/ReShape\\_Instructions\\_For\\_Use.pdf](https://reshapeready.com/wp-content/uploads/2015/07/ReShape_Instructions_For_Use.pdf).



17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Figure 1. *ReShape* Dual Balloon in the Stomach

235. Claim 19 generally recites the obesity treatment system of claim 16, further comprising a flexible central spine structure spanning a gap between and connecting the plurality of adjacent, spaced apart inflatable space-filling compartments.

236. The Infringing Instrumentalities infringe claim 19 of the '367 patent. The flexible central spine element is illustrated in the video provided on ReShape's website, a frame from which is reproduced below. *See* <https://reshapeready.com/reshape-cc/>; *see also* <https://www.youtube.com/watch?v=U91FsjtMf3o>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28






Figure 1. *ReShape* Dual Balloon in the Stomach

Accordingly, on information and belief, the ReShape Balloon’s flexible central spine structure spans a gap between and connects the plurality of adjacent, spaced apart inflatable space-filling compartments.


237. Claim 20 generally recites the obesity treatment system of claim 19, wherein the flexible central spine structure is in fluid communication with the valve system.

238. Upon information and belief, the Infringing Instrumentalities infringe claim 20 of the ‘367 patent. The flexible central spine element is illustrated in the video provided on ReShape’s website, a frame from which is reproduced below.

See <https://reshapeready.com/reshape-cc/>; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>.



Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and valves are carried by the flexible central spine as shown below:




Accordingly, on information and belief, the ReShape Balloon's flexible central spine structure is in fluid communication with the valve system.

239. Claim 21 generally recites the obesity treatment system of claim 20, wherein the flexible central spine structure encloses an inflation lumen for introducing the fluid into the plurality of inflatable space-filling compartments.


240. Upon information and belief, the Infringing Instrumentalities infringe claim 21 of the '367 patent. The flexible central spine element is illustrated in the video provided on ReShape's website, a frame from which is reproduced below.

See <https://reshapeready.com/reshape-cc/>; see also <https://www.youtube.com/watch?v=U91FsjtMf3o>.





Further, ReShape's patent, U.S. 8,142,469, shows that the inflation lumens and valves are carried by the flexible central spine as shown below:



Accordingly, on information and belief, the ReShape Balloon's flexible central spine structure encloses an inflation lumen for introducing the fluid into the plurality of inflatable space-filling compartments.

241. On information and belief, the Infringing Instrumentalities are used marketed, provided to, and/or used by or for each of ReShape Medical LLC and ReShape Lifesciences' partners, clients, customers and end users across the country and in this District.

242. On information and belief, each of ReShape Medical LLC and ReShape Lifesciences has been aware of the existence of the '367 patent since its issuance.

243. On information and belief, since at least the time each of ReShape Medical LLC and ReShape Lifesciences has been aware of the '367 patent, it has

1 induced and continues to induce others to infringe at least one claim of the '367  
2 patent under 35 U.S.C. § 271(b) by, among other things, and with specific intent  
3 or willful blindness, actively aiding and abetting others to infringe, including but  
4 not limited to each of ReShape Medical LLC and ReShape Lifesciences' partners,  
5 clients, customers, and end users, whose use of the ReShape Medical Duo Balloon  
6 constitutes direct infringement of at least one claim of the '367 patent.

7 244. In particular, each of ReShape Medical LLC and ReShape  
8 Lifesciences' actions that aid and abet others such as its partners, customers,  
9 clients, and end users to infringe include advertising and distributing the ReShape  
10 Medical Duo Balloon, and providing instruction materials, training, and services  
11 regarding the ReShape Medical Duo Balloon. On information and belief, each of  
12 ReShape Medical LLC and ReShape Lifesciences has engaged in such actions  
13 with specific intent to cause infringement or with willful blindness to the resulting  
14 infringement because, on information and belief, it has had actual knowledge of  
15 the '367 patent and knowledge that its acts were inducing infringement of the '367  
16 patent since at least the date the '367 patent issued.

17 245. Upon information and belief, each of ReShape Medical LLC and  
18 ReShape Lifesciences is liable as a contributory infringer of the '367 patent under  
19 35 U.S.C. § 271(c) by offering to sell, selling and importing into the United States  
20 gastric balloon technology to be especially made or adapted for use in an  
21 infringement of the '367 patent. The Infringing Instrumentalities are a material  
22 component for use in practicing the '367 patent and are specifically made and are  
23 not a staple article of commerce suitable for substantial non-infringing use.

24 246. ReShape Medical LLC and ReShape Lifesciences' infringement of  
25 the '367 patent has been, and continues to be knowing, intentional, and willful, in  
26 whole or in part because each of ReShape Medical LLC and ReShape  
27 Lifesciences has been aware of the '367 patent since its issuance and continues to  
28 engage in infringing conduct. ReShape Medical, Inc. had knowledge of all major

1 aspects of Fulfillium’s business plans, including trade secrets divulged pursuant to  
2 an oral agreement of confidentiality. ReShape Medical, Inc. knew that Fulfillium  
3 was actively engaged in patenting its gastric balloon technology. Further,  
4 ReShape Medical, Inc. was fully aware that its technology would copy many  
5 aspects of Dr. Chen’s inventions because it was developed after and with  
6 knowledge of Dr. Chen’s designs. The fact that ReShape Medical, Inc. knew of  
7 Dr. Chen’s patents and believed those patents to be relevant to ReShape Medical,  
8 Inc.’s gastric balloon technology is demonstrated by ReShape Medical, Inc.’s  
9 citation of Dr. Chen’s patents as relevant prior art when attempting to procure its  
10 own patents. For instance, in December 2012 ReShape Medical, Inc. filed an  
11 information disclosure statement with the United States Patent and Trademark  
12 Office indicating that Dr. Chen’s previous patent applications were relevant to  
13 ReShape Medical, Inc.’s pending patent application directed to the ReShape  
14 Balloon. Additionally, ReShape Medical, Inc. (and consequently ReShape  
15 Medical LLC and ReShape Lifesciences) received explicit notice of the ‘367  
16 patent via letter on November 14, 2017.

17 247. Each of ReShape Medical LLC and ReShape Lifesciences’ acts of  
18 infringement of the ‘367 patent have caused and will continue to cause Fulfillium  
19 damages for which Fulfillium is entitled to compensation pursuant to 35 U.S.C. §  
20 284.

21 248. Each of ReShape Medical LLC and ReShape Lifesciences’ acts of  
22 infringement of the ‘367 patent have caused and will continue to cause Fulfillium  
23 immediate and irreparable harm unless such infringing activities are enjoined by  
24 this Court pursuant to 35 U.S.C. § 283. Fulfillium has no adequate remedy at law.

25 249. This case is exceptional and, therefore, Fulfillium is entitled to an  
26 award of attorneys’ fees pursuant to 35 U.S.C. § 285.

1 **JURY DEMAND**

2 Pursuant to Rule 38 of the Federal Rules of Civil Procedure, Plaintiff  
3 demands a trial by jury on all issues triable as such.

4 **PRAYER FOR RELIEF**

5 WHEREFORE, Fulfillium respectfully requests that the Court enter  
6 judgment against Defendants as follows:

7 A. An adjudication that each of ReShape Medical LLC and SV Health  
8 has misappropriated and conspired to misappropriate Fulfillium's trade secrets;

9 B. An adjudication that Fulfillium have judgment against each  
10 Defendant for compensatory damages in the amount not less than the sum of \$50  
11 million;

12 C. An adjudication that each of ReShape Medical LLC and SV Health  
13 be ordered to disgorge and restore to Fulfillium the monies by which they have  
14 been unjustly enriched by virtue of their trade secret misappropriation, in an  
15 amount no less than \$50 million;

16 D. An adjudication that Fulfillium have judgment against each of  
17 ReShape Medical LLC and SV Health for exemplary damages under Civil Code §  
18 3624.3(c) and/or Mass. Gen. Laws ch. 93, § 42-42A in the amount not less than  
19 twice the amount of Fulfillium's actual damage or the amounts by which each of  
20 ReShape Medical LLC and SV Health has been unjustly enriched;

21 E. An adjudication that each Defendant be ordered to deliver up to  
22 Fulfillium all documents, electronic and otherwise, containing Fulfillium trade  
23 secret information, and all products developed using such information;

24 F. An adjudication that each Defendant and its subsidiaries, affiliates,  
25 parents, successors, assigns, officers, agents, servants, employees, attorneys, and  
26 all persons acting in concert or in participation with them, or any of them, be  
27 temporarily and preliminarily enjoined during the pendency of this action, and  
28

1 permanently enjoined thereafter, from further misappropriation, disclosure and/or  
2 use of any Fulfillium trade secret information;

3 G. An adjudication that ReShape Medical LLC and ReShape  
4 Lifesciences have infringed the ‘915, ‘930, and ‘367 patents in violation of 35  
5 U.S.C. § 271;

6 H. A granting of an injunction permanently enjoining ReShape Medical  
7 LLC and ReShape Lifesciences, its employees, agents, officers, directors,  
8 attorneys, successors, affiliates, subsidiaries and assigns, and all of those in active  
9 concert and participation with any of the foregoing persons or entities from  
10 infringing, contributing to the infringement of, or inducing infringement of the  
11 ‘915, ‘930, and ‘367 patents;

12 I. An order to ReShape Medical LLC and ReShape Lifesciences to  
13 account and pay damages adequate to compensate Fulfillium for ReShape Medical  
14 LLC and ReShape Lifesciences’ infringement of the ‘915, ‘930, and ‘367 patents,  
15 with pre-judgment and post-judgment interest and costs, pursuant to 35 U.S.C.  
16 § 284, and an accounting of all infringing acts not presented at trial;

17 J. An order that the damages award be increased up to three times the  
18 actual amount assessed, pursuant to 35 U.S.C. § 284;

19 K. A declaration that this case is exceptional under 35 U.S.C. § 285, and  
20 an award of Fulfillium’s reasonable costs and fees, including attorneys’ fees, with  
21 interest; and

22 L. An award to Fulfillium of such other and further relief as this Court  
23 deems just and proper.

1 Dated: May 25, 2018

DEVLIN LAW FIRM LLC

3 /s/ Timothy Devlin

4 Timothy Devlin (pro hac filed)

5 tdevlin@devlinlawfirm.com

6 James Gorman III (pro hac to be filed)

7 jgorman@devlinlawfirm.com

8 1306 N. Broom St., 1<sup>st</sup> Floor

Wilmington, Delaware 19806

10 Telephone: (302) 449-9010

11 Facsimile: (302) 353-4251

12 LAW OFFICES OF SETH W. WIENER

GARDELLA GRACE P.A.

14 /s/ Seth W. Wiener

/s/ Greg H. Gardella

15 Seth W. Wiener (Bar No. 203747)

Greg H. Gardella (pro hac to be filed)

16 sethwiener@yahoo.com

ggardella@gardellagrace.com

17 9107 Wilshire Boulevard, Suite

PO Box 51977

18 450

Washington, DC 20091

19 Beverly Hills, CA 90210

Telephone: (703) 556-9600

20 Telephone: (925) 487-5607

Facsimile: (703) 740-4541

22 *Attorneys for Plaintiff Fulfillium, Inc.*

**DEMAND FOR A JURY TRIAL**

1  
2 Plaintiff Fulfillium, Inc. requests a trial by jury on all issues for which it is  
3 entitled to a jury.

4 Dated: May 25, 2018

DEVLIN LAW FIRM LLC

5  
6 /s/ Timothy Devlin  
7 Timothy Devlin  
8 1306 N. Broom Street, First Floor  
9 Wilmington, DE 19806  
10 (302)-449-9010  
11 tdevlin@devlinlawfirm.com  
12 *Counsel for Fulfillium, Inc*  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28